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Abstract 
Novel Vaccine Immunogens from Rare HIV-1 Controllers that 
Possess Broadly Neutralizing Antibodies 
 
Jennie M. Hutchinson 
 
After over 35 years of research, a prophylactic HIV vaccine remains elusive. 
However, the discovery of potent broadly neutralizing antibodies (bNAbs) in some 
individuals (elite neutralizers) and other individuals that control HIV infection 
without anti-retroviral drugs (controllers) have renewed optimism that an effective 
vaccine may be possible. The production of bNAbs does not correlate with improved 
disease outcomes because they take too long to develop and the virus typically 
outpaces the antibody response. However, passive transfer of bNAbs prior to 
infection is protective in non-human primate models. Thus, a vaccine capable of 
eliciting bNAbs prior to infection may provide protective immunity. The sole target 
of bNAbs is the viral spike, a trimer of envelope glycoproteins (Env). Although it is 
now possible to produce recombinant Envs with epitopes that bind bNAbs, these have 
failed to elicit bNAbs. Epitopes recognized by bNAbs are inherently poor 
immunogens due to the densely packed glycan shield that covers the majority of the 
surface. Previous HIV vaccines were based on Envs without regard for the immune 
response in virus donors. Here, for the first time, we studied Envs from two rare 
individuals that controlled viral load and produced bNAbs. From each individual, 
envs were cloned and used to construct 20 pseudotype viruses. These were then 
screened for neutralization sensitivity against a panel of prototypic monoclonal 
 viii 
bNAbs. Comparative sequence analysis revealed two features that may have 
contributed to the robust immune response:  (1) a major reduction (35%) in the 
number of potential N-linked glycosylation sites in gp120 and (2) two extra cysteine 
residues in the V1/V2 region. One env from each individual was expressed and used 
for antibody binding assays and rabbit immunization studies. Antibody responses to 
the novel immunogens were compared to MN rgp120, used in the only clinical trials 
that has shown efficacy in humans. A minimally glycosylated immunogen elicited an 
improved cross-reactive neutralization response compared to other clade B Envs, 
including MN. This work demonstrated that Envs from individuals with the elite 
neutralizer/controller phenotype possess unusual structural features that may have 
enhanced the immune response and represent a new source of HIV vaccine 
immunogens.  
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We stand on the shoulders of giants. 
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 1 
Introduction 
In 1983, human immunodeficiency virus (HIV) was isolated and identified as the 
pathogen causing acquired immunodeficiency syndrome (AIDS)(Barre-Sinoussi et 
al., 1983). After over 35 years of global prevention and treatment efforts, HIV 
remains a significant public health crisis. Since the start of the pandemic, 75 million 
people have been infected with HIV and 32 million have died from AIDS-related 
illnesses (UNAIDS, 2019a). Like all infectious diseases, HIV/AIDS 
disproportionately impacts the most disadvantaged members of society. Globally, 
AIDS-related illnesses are the leading cause of death in women of reproductive age 
(UNAIDS, 2019a). In the United States, black Americans face an increased burden 
primarily due to socio-economic status and mass incarceration (Shrage, 2016), 
composing 41% of new HIV infections despite representing only 12% of the 
population (CDC, 2018). While black American women tend to have the same, if not 
safer sex practices (Hallfors et al., 2007; Reece et al., 2010), they are twenty-times as 
likely to become infected with HIV than their white counter parts due to social 
injustices (CDC, 2018). Disparities across the continuum of care make a prophylactic 
vaccine the most viable solution for HIV eradication and research efforts should focus 
on the most affected communities (Fauci, 2017). 
 
Challenges to developing an HIV-1 envelope subunit vaccine 
A primary goal of HIV-1 vaccine design is to produce an immunogenic HIV-1 
envelope glycoprotein (Env), the sole target of neutralizing antibodies. This has 
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proved a formidable challenge due to viral adaptations to evade the immune system. 
The HIV virion surface is primarily composed of host-derived plasma membrane with 
a sparse number (7 – 14) of conformationally dynamic viral spikes (Zhu et al., 2006). 
The viral spike is a homotrimer of gp160s (Envs) that have been cleaved by furin into 
non-covalently linked heterodimers of gp120 and gp41 (Seabright et al., 2019). The 
gp41 portion is membrane-bound and also present on the virion surface as gp41 
“stumps,” which act as a decoy for immune recognition (Seabright et al., 2019). 
Similarly, non-functional monomeric gp120 are shed by the virus (Seabright et al., 
2019). The extracellular gp120 is described by five constant regions (C1 – C5) and 
five variable regions (V1 – V5). All published crystal structures of Env show gp120 
with 18 cysteine residues that form 9 disulfide bonds and typically have 25 – 26 N-
linked glycans (Behrens et al., 2016; Lasky et al., 1986; Wei et al., 2003). These host-
produced glycans compose half the mass of gp120 and form a “glycan shield” that is 
poorly immunogenic (Behrens et al., 2016; Lasky et al., 1986; Wei et al., 2003). Env 
glycans are not fully processed due to steric hindrance (Doores et al., 2010) resulting 
in high-mannose glycoforms. Variations in glycoforms and glycan occupancy 
significantly alter antigenic structures (Rudd and Dwek, 1997). 
HIV exhibits unprecedented viral diversity. There are two major types, HIV-1 
and HIV-2, which likely emerged from distinct zoonosis events from chimpanzee 
viruses (CPZ) and simian immunodeficiency virus (SIV), respectively (Korber et al., 
2001). HIV-1 is substantially more prevalent and further divided into groups M, N, 
and O. More than 90% of HIV-infections are from HIV-1 group M, which includes 
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clades A – K and circulating recombinant forms (CRF)(Korber et al., 2001). There is 
wide variability even within one person at a single timepoint, where genetic diversity 
is comparable to global influenza in a given year (Korber et al., 2001). HIV’s 
extraordinary genetic heterogeneity is due to error-prone reverse transcription, fast 
replication, and frequent recombination (Perelson et al., 1996; Preston et al., 1988; 
Zhang et al., 2010). In addition, viral RNA is integrated into the host genome, 
creating a latent reservoir that can reseed infection with ancestral variants. 
 
Antibody response to HIV infection 
HIV infection is initiated by one or a few transmitter/founder viruses (T/F)(Derdeyn 
et al., 2004; Keele et al., 2008). Cell entry requires gp120 binding to the CD4 receptor 
and a co-receptor, either CCR5 and/or, later in disease progression, CXCR4 
(Seabright et al., 2019). Non-neutralizing antibodies targeting gp41 develop 1 – 2 
weeks after infection (Mikell et al., 2011), followed by gp120-specific antibodies that 
often target the V3 loop (Tomaras et al., 2008) and CD4-binding site (Lynch et al., 
2012). These initial non-neutralizing antibodies elicit cell-mediated responses, 
including antibody-dependent cellular cytotoxicity and other antiviral activity (Baum 
et al, 1996). The first neutralizing antibodies that appear are strain-specific and can 
neutralize some, but not all, autologous virus (Wei et al., 2003). The virus evolves 
quickly, escaping the antibody response and driving formation of antibodies 
recognizing new epitopes. There are continual rounds of viral escape and antibody 
maturation, with the virus usually outpacing the immune response (Bhiman et al., 
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2015; Bonsignori et al., 2016; Doria-Rose et al., 2014; Euler et al., 2010; Freund et 
al., 2017; Wu et al., 2010; Zhou et al., 2013). After 1 – 3 years, the virus usually 
undergoes extensive diversification and broadly neutralizing antibodies (bNAbs) 
emerge in ~30% of people (Sather et al., 2009). 
 There are significant challenges to developing bNAbs. Antibodies must 
penetrate or bind to the glycan shield (Doria-Rose et al., 2009; Euler et al., 2010; 
Hraber et al., 2014; van Gils et al., 2009). Production of glycan-targeting antibodies 
requires bypassing a negative selection process designed to prevent auto-reactive 
antibodies (Wardemann et al., 2003). Binding affinity to glycans tends to be lower 
(Cohen, 2015) and bNAbs usually require multivalent interactions (Kong et al., 
2013). The extensive antibody maturation process prior to neutralization breadth can 
result in antibodies with unusual characteristics, including long CDRH3 regions and 
high level of somatic hypermutation (Andrabi et al., 2015; Klein et al., 2013). Despite 
these obstacles, half of individuals produce antibodies with significant cross reactivity 
(Hraber et al., 2014), suggesting that it is possible that a vaccine could elicit bNAbs. 
Less than 1% of individuals are elite neutralizers, defined by having sera with 
highly potent cross-reactive neutralization activity, able to neutralize viruses from a 
least four different clades at an average dilution of 1:300 or greater (Simek et al., 
2009). However, even in these individuals, neutralization breadth does not correlate 
with improved disease outcomes (Bhiman et al., 2015; Bonsignori et al., 2016; Doria-
Rose et al., 2014; Euler et al., 2010; Freund et al., 2017; Piantadosi et al., 2009; Wu et 
al., 2010; Zhou et al., 2013). While bNAbs do not provide protection in natural 
 5 
infection, passive immunization studies in non-human primates have demonstrated 
that bNAbs can provide protective immunity (Baba et al., 2000; Hessell et al., 2010, 
2009; Mascola et al., 2000, 1999; Moldt et al., 2012; Parren et al., 2001; Shibata et 
al., 1999). Thus, a vaccine capable of eliciting potent bNAbs, like those found in elite 
neutralizers, remains a primary goal. 
 
Viral control 
Some individuals control HIV infection and maintain low viral loads, which correlate 
with slow disease progression (Okulicz et al., 2009). There are multiple biological 
mechanisms that contribute to viral control but vary from patient to patient (Lambotte 
et al., 2009; Pereyra et al., 2008). Human leukocyte antigen alleles that encode for the 
major histocompatibility complex proteins account for ~15% of individuals with low 
viral load (Fellay et al., 2009) through improved presentation of immunogenic 
structures and interactions with natural killer cells (Tomescu et al., 2012). Cell-
mediated responses also play a significant role, primarily through CD8+ T cell 
responses (Leitman et al., 2017b; Pereyra et al., 2014) and antibody-mediated cellular 
cytotoxicity (Ackerman et al., 2016; Baum et al., 1996; Johansson et al., 2011; 
Lambotte et al., 2009; Madhavi et al., 2017). Virological factors can lead to viral 
control, such as infection with attenuated strains (Lassen et al., 2009; Pereyra et al., 
2008). Ongoing research efforts seek to further elucidate pathways to viral control, 
the closest manifestation of natural immunity. 
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Current strategies for developing HIV envelope subunit vaccine 
To date, vaccine candidates have failed to consistently elicit the production of bNAbs 
and multiple strategies are being explored to enhance immunogenicity (Andrabi et al., 
2018; Gilbert et al., 2010; Kwong and Mascola, 2018; Lian et al., 2005; Mascola et 
al., 1996; Montefiori et al., 2012). Extensive research has led to the production of 
trimeric Envs with antigenic structures capable of binding to all major classes of 
bNAbs, i.e., those that target V2-glycans, V3-glycans, CD4-binding site, membrane 
proximal external region (MPER), and gp120-gp41 interface (Julien et al., 2013a; Sok 
and Burton, 2018). However, these trimeric Envs have so far failed to consistently 
elicit bNAbs in immunization studies. Sequential immunizations strategies are being 
employed to improve immunogenicity and direct the neutralization response to sites 
of vulnerability. One strategy is based on longitudinal studies examining the co-
evolution of Envs and antibody maturation pathway of bNAbs, where immunogens 
are designed to mimic viral evolution in an attempt to recapitulate the corresponding 
bNAb ontogeny (de Taeye et al., 2016). An alternative strategy is to use 
deglycosylated Env trimers, which have been shown to increase immunogenicity, 
followed by boosts with Envs containing additional glycans (Dubrovskaya et al., 
2019). Another approach is using properly folded and glycosylated Env scaffolds in 
order to focus the antibody response to neutralizing epitopes and limit responses to 
non-neutralizing immunodominate regions (Chung et al., 2012; Hoffenberg et al., 
2013; Morales et al., 2014a, 2016; Ofek et al., 2010, 2010; Yu et al., 2012). 
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Here, we explore a new source of potentially immunogenic Envs, those 
isolated from ART-naïve viral controllers that produce bNAbs. The majority of Envs 
that have been studied were derived from individuals without regard for disease 
phenotype in the virus donor. Envs isolated from elite neutralizers may share 
immunogenic features that induced the production of potent bNAbs but antigen 
selection is challenging due to viral diversification. To overcome this, we looked for 
elite neutralizers that maintained viral control, reasoning that the smaller viral 
population with less Env diversity may result in the identification of Envs that are 
more closely related to those that induced bNAbs. In addition, Envs from viral 
controllers may have other immunogenic features that contributed to antiviral 
activity. However, it was unclear if we could obtain samples from ART-naïve 
individuals with the elite neutralizer/controller phenotype. ART-naïve samples are 
increasingly rare because the current standard of care includes ART shortly after 
diagnosis. Also, it has previously been reported that viral controllers have less 
neutralization breadth (Doria-Rose et al., 2010). Identification of individuals with the 
elite neutralizer/controller phenotype required extensive screening for neutralization 
breadth in 136 archival samples from ART-naïve viral controllers in the SCOPE and 
WIHS longitudinal studies. For the first time, we have characterized Envs from 
individuals with the elite neutralizer/controller phenotype and found structural 
features that may have contributed to their robust immune response. These studies 
demonstrate that Envs isolated from the elite neutralizer/controller phenotype are a 
promising new source for HIV immunogens. 
 8 
Chapter 1:  SCOPE cohort study 
 
Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That 
Produces Broadly Neutralizing Antibodies 
 
Published in Frontiers Immunology, 15 May 2019 
 
Authors:  Jennie M. Hutchinson1, Kathryn A. Mesa1, David L. Alexander1, Bin Yu1, 
Sara M. O’Rouke1, Kay L. Limoli2, Terri Wrin2, Steven G. Deeks3, and Phillip W. 
Berman1 
 
Affiliations:  1Department of Biomolecular Engineering, University of California, 
Santa Cruz, Santa Cruz, CA, United States, 2Monogram Biosciences, South San 
Francisco, CA, United States, 3Department of Medicine, University of California, San 
Francisco, San Francisco, CA, United States 
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Abstract 
Although it is now possible to produce recombinant HIV envelope glycoproteins 
(Envs) with epitopes recognized by the 5–6 major classes of broadly neutralizing 
antibodies (bNAbs), these have failed to consistently stimulate the formation of 
bNAbs in immunized animals or humans. In an effort to identify new immunogens 
better able to elicit bNAbs, we are studying Envs derived from rare individuals who 
possess bNAbs and are able to control their infection without the need for anti-
retroviral drugs (elite supressors or ES), hypothesizing that in at least some people the 
antibodies may mediate durable virus control. Because virus evolution in people with 
the ES only phenotype was reported to be limited, we reasoned the Env proteins 
recovered from these individuals may more closely resemble the Envs that gave rise 
to bNAbs compared to the highly diverse viruses isolated from normal progressors. 
Using a phenotypic assay, we screened 25 controllers and identified two for more 
detailed investigation. In this study, we examined 20 clade B proviral sequences 
isolated from an African American woman, who had the rare bNAb/ES phenotype. 
Phylogenetic analysis of proviral envelope sequences demonstrated low genetic 
diversity. Envelope proteins were unusual in that most possessed two extra cysteines 
within an elongated V1 region. In this report, we examine the impact of the extra 
cysteines on the binding to bNAbs, virus infectivity, and sensitivity to neutralization. 
These data suggest structural motifs in V1 can affect infectivity, and that rare viruses 
may be prevented from developing escape. 
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Introduction 
Despite the widespread availability of anti-retroviral drugs, recent studies suggest that 
an HIV vaccine will still be required to control and eliminate the spread of this virus 
(Fauci, 2017; Medlock et al., 2017). Over the last decade, evidence has accumulated 
from passive immunization studies to suggest that a vaccine that elicits broadly 
neutralizing antibodies (bNAbs) to the HIV envelope glycoprotein (Env), prior to 
infection, can provide protective immunity against HIV (Barouch et al., 2013; 
Bournazos et al., 2014; Caskey et al., 2015; Jacobson et al., 1993; Klein et al., 2014; 
Ledgerwood et al., 2015; Shingai et al., 2014, 2013; Stiegler et al., 2002). Although 
considerable progress has been made in developing immunogens, such as properly 
folded trimeric Envs (Derking et al., 2015; Georgiev et al., 2015; Julien et al., 2013a; 
McLellan et al., 2011; Pejchal et al., 2011; Sanders et al., 2015; Sok et al., 2014; 
Yang et al., 2018) that accurately replicate the antigenic structures of the 5–6 major 
epitopes recognized by bNAbs (Kwong and Mascola, 2012; van Gils and Sanders, 
2013; Walker et al., 2010), none have been effective in eliciting protective 
neutralizing antibodies (Andrabi et al., 2018; Gilbert et al., 2010; Kwong and 
Mascola, 2018; Lian et al., 2005; Mascola et al., 1996; Montefiori et al., 2012). Thus, 
while the immunogens developed to date possess the proper antigenic structure, the 
epitopes themselves appear to be poorly immunogenic, and we have not yet replicated 
the immunogenic structure required to elicit bNAbs. 
A number of different strategies are being pursued to improve recombinant 
Env immunogenicity. One approach involves immunization with properly folded and 
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glycosylated fragments of Env proteins (Chung et al., 2012; Hoffenberg et al., 2013; 
Morales et al., 2014a, 2016; Yu et al., 2012) in hopes of selectively stimulating the 
formation of bNAbs, while precluding the possibility of stimulating antibodies to 
immunodominant non-neutralizing epitopes. A second approach to this problem has 
been to employ guided immunization strategies, using a prime-boost series that 
reconstruct the ontogeny of bNAb evolution (Andrabi et al., 2018; Bonsignori et al., 
2016; Escolano et al., 2016; Gao et al., 2014; Kwong and Mascola, 2018; Liao et al., 
2013; Pancera et al., 2017). A third approach considers the possibility that Envs 
recovered from rare individuals with high levels of bNAbs, termed elite neutralizers 
(ENs), may be more effective in eliciting bNAbs than Envs from normal progressors 
that failed to produce bNAbs. However, the task of antigen selection from ENs is 
complicated by the fact that bNAbs are typically detected 2 years or more after 
infection (Gray et al., 2011; Landais et al., 2016). By this time, Env sequences have 
diversified considerably and most circulating plasma viruses are enriched for 
neutralization resistant variants (Albert et al., 1990; Wei et al., 2003). Thus, finding 
the precursor envelope sequences likely to have elicited bNAbs in an EN is a 
formidable challenge. 
Here, we consider whether Env proteins closely resembling those that 
stimulated the formation of bNAbs can be recovered from rare individuals where 
virus evolution has been restricted or slowed, but still possess bNAbs. Previous 
studies have reported that virus evolution is considerably limited in individuals 
termed elite suppressors (ES) that are defined by their ability to limit virus replication 
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without the need for antiretroviral drugs (Bailey et al., 2006; Bello et al., 2007, 2004; 
Casado et al., 2010; Lassen et al., 2009; Roy et al., 2017; Sandonís et al., 2009; 
Scutari et al., 2018; Smith et al., 2013; Wang et al., 2003). Less than 1% of HIV-
positive individuals possess the ES phenotype, meaning their viral load is less than 
detectable levels, i.e., <50 or <75 RNA copies/ml, for more than a year without anti-
retroviral treatment (Okulicz et al., 2009). The ability to control viral load correlates 
with improved disease outcomes but the mechanism remains unclear. ESs exhibit 
heterogeneous immune responses but virus-specific CD8+ T cell responses appear to 
be a dominant feature (Lassen et al., 2009; Leitman et al., 2017a, 2017b; Pereyra et 
al., 2014, 2008; Walker and Yu, 2013). ESs typically have viral populations with both 
limited genetic diversity and lower replication rates than normal progressors, 
including ENs (Bailey et al., 2006; Bello et al., 2007, 2004; Casado et al., 2010; 
Lassen et al., 2009; Roy et al., 2017; Sandonís et al., 2009; Scutari et al., 2018; Smith 
et al., 2013; Wang et al., 2003). In addition, HIV in ESs may be constrained due to 
their fitness landscape, where mutational escape is limited due to the high fitness cost 
of mutations (Bailey et al., 2006; Brumme et al., 2011; Fernàndez et al., 2007; Lassen 
et al., 2009; Lobritz et al., 2011; Miura et al., 2009; Mwimanzi et al., 2013; Zaunders 
et al., 2011). Although most ESs fail to produce bNAbs, rare individuals possess 
bNAbs with neutralization breadth and exhibit the ES phenotype (bNAbs/ES 
phenotype). The restrictions on virus evolution in these individuals raised the 
possibility that Envs from individuals with the bNAb/ES phenotype may be more 
closely related to those that elicited the production of bNAbs than normal progressors 
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with the EN phenotype. Therefore, we wondered if Env proteins from ESs that 
produce bNAbs might be enriched for unusual structural features, possibly related to 
epitope stabilization, antigen processing, or antigen presentation, that may have 
enhance immunogenicity leading to the formation of bNAbs. Here, we describe the 
recovery of 20 functional proviral sequences isolated from an individual who is an 
elite suppressor (viral load <75 HIV RNA copies/ml for over 4 years) and possesses 
bNAbs. We show that the majority of these sequences possess an unusual number of 
cysteines that may form an additional disulfide bond. 
 
Materials and Methods 
Clinical Specimens 
Twenty-nine blinded archival plasma specimens (0.5–2.0 ml) from anti-retroviral 
therapy (ART) naïve men and women were obtained from the SCOPE study cohort 
(University of California, San Francisco, San Francisco, CA). Twenty-five of the 
specimens were from individuals previously identified as elite supressors (<75 HIV 
RNA copies/ml for 12+ months without ART). Four specimens were from normal 
progressors. Specimens were collected according to an Institutional Review Board 
(IRB) approved protocol for which study participants provided written consent and 
were seen at regular intervals. At each visit, subjects took a confidential 
questionnaire, were invited to participate in a medical exam for additional studies, 
and a blood sample was taken. After screening plasma for virus neutralizing 
antibodies (described below) an archival contemporaneous sample of non-viable 
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PBMCs was obtained from an individual (designated as “EN3”) with the dual ES and 
broadly neutralizing antibody phenotype for sequence analysis. 
Samples from a separate cohort, which included patient “EN1,” were collected 
by a physician under an Institutional Review Board (IRB) approved protocol from 
volunteers attending a regional center for recruitment in the San Francisco Bay Area. 
Inclusion criteria stipulated HIV-positive men and women 18–65 years of age, HIV 
ELISA or Western Blot positive for at least 1 year prior to screening, and who have 
never received anti-retroviral therapy (including post-exposure prophylaxis). An 
initial 10 mL of blood was collected into two EDTA tubes and plasma were aliquoted 
into cryovials and tested for bNAbs (described below). Four individuals with high 
titers of bNAbs were asked to participate in a 500 mL blood draw in a clinical setting. 
The blood was processed by a commercial laboratory using standard techniques and 
the PBMCs and plasma were separated, aliquoted, and cryopreserved under 
conditions that preserved plasma virus RNA and cell associated provirus DNA. The 
specimens were stored at −80°C until further analysis. 
 
Screen for Neutralization Breadth 
Plasma samples were tested for virus neutralizing activity at Monogram Biosciences 
(South San Francisco, CA) in a standard pseudotype virus neutralization assay 
(PhenoSense®) using a panel of either 22 or 26 international isolates widely used in 
HIV vaccine research. Briefly, pseudotype viruses were prepared by cotransfecting 
HEK293 cells (American Type Culture Collection [ATCC], Manassas, VA) with an 
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Env expression vector and an Env-deficient HIV-1 genomic vector carrying a 
luciferase reporter gene. Serial dilutions of mAbs or plasmas/sera were incubated 
with pseudotype viruses for 1 h prior to addition of U87 cells expressing CD4, CCR5, 
and/or CXCR4. The Z23 serum was used at an initial dilution of 1/100 and was 
included as an internal control in all experiments. Neutralization data are reported as 
50% inhibitory dilutions (ID50s) for serum or plasma calculated from 5 point serum 
dilution curves. The virus controls included pseudoviruses prepared from the 
neutralization-sensitive HIV-1 isolate NL4-3 and the less neutralization-sensitive 
primary isolate JRCSF. The negative-control virus consisted of pseudotype viruses 
prepared from the envelope of the amphotropic murine leukemia virus (aMLV). HIV-
1 neutralization titers were considered significant only if they were >3 times higher 
than the aMLV titers. The neutralization assays were performed according to good 
laboratory practice (GLP) and using protocols approved under Clinical Laboratory 
Improvement Amendments (CLIA). Each assay included acceptability criteria to 
ensure that inter-assay variation between ID50s, measured with reference standards, 
fell within 2.5-fold 95% of the time (Petropoulos et al., 2000). 
 
Recovery of Env Sequences and Tropism Assay 
An attempt was made to recover virus sequences from plasma and PBMCs from EN3. 
Due to the low copy number, the PhenoSense® assay system of Monogram 
Biosciences was unable to recover full-length functional clones of HIV envelope 
genes from plasma. However, full-length functional clones of HIV envelope genes 
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were recovered from provirus DNA in PBMCs. A unique feature of Monogram 
Biosciences' assay system is a selection step for functional Envs that eliminates 
defective and noninfectious envelope sequences common in proviral specimens. Viral 
tropism was determined using the Trofile® DNA assay system from Monogram 
Biosciences. The DNA sequences of the resulting clones were determined by Sanger 
chain termination sequencing and analyzed for genetic clade using the Recombinant 
Identification Program (RIP) HIV clade assignment tool (Siepel et al., 1995). 
 
Phylogenetic Analyses 
The gp160 sequences were aligned in Geneious v5.6.7 (Kearse et al., 2012) using the 
MUSCLE algorithm (Edgar, 2004). The sequence of the JRCSF isolate of HIV was 
designated as the outgroup. The evolutionary history was inferred by using the 
Maximum Likelihood method based on the General Time Reversible model (Nei and 
Kumar, 2000). The tree with the highest log likelihood (−8098.9704) is shown. The 
percentage of trees in which the associated taxa clustered together is shown next to 
the branches. Initial tree(s) for the heuristic search were obtained automatically by 
applying the Neighbor-Joining method to a matrix of pairwise distances estimated 
using the Maximum Composite Likelihood (MCL) approach. A discrete Gamma 
distribution was used to model evolutionary rate differences among sites [5 categories 
(+G, parameter = 0.3273)]. The tree is drawn to scale, with branch lengths measured 
in the number of substitutions per site. The analysis involved 32 proviral nucleotide 
sequences (20 from EN3, 11 from EN1, an elite neutralizer with normal progression, 
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and JRCSF). All positions with <95% site coverage were eliminated. That is, fewer 
than 5% alignment gaps, missing data, and ambiguous bases were allowed at any 
position. There were a total of 2505 positions in the final dataset. Evolutionary 
analyses were conducted in MEGA6 (Tamura et al., 2013). 
 
Expression of Recombinant gp120 
Codon-optimized gene sequences were used for the expression of gp120. Synthetic 
gp120 genes (Invitrogen Inc., Waltham, MA) were inserted into an in-house plasmid 
expression vector (pCF1) containing a CMV promoter using standard techniques. 
PCR site-directed mutagenesis was performed to create variants of gp120 using a 
standard protocol for Gibson Assembly (New England Biolabs, Inc, Ipswich, MA). 
Recombinant plasmid sequences were confirmed by Sanger sequencing (University 
of California Sequencing Facility, Berkeley, CA). DNA was extracted and purified 
with a maxiprep kit (Qiagen, Redwood City, CA). For gp120 expression studies, 
envelope genes were transiently transfected into a HEK293 cell variant lacking the 
enzyme N-acetylglucosaminyltransferase I (HEK293S GnTI-, ATCC® CRL-
3022TM)(Morales et al., 2014a). The cells were transfected using polyethylenimine, 
grown in serum free cell culture medium (FreeStyle TM 293F; Invitrogen, Inc., 
Waltham, MA), and harvested after 5 days of growth. The gp120 proteins were 
expressed as fusion proteins that possessed an N-terminal flag epitope of 27 amino 
acids from herpes simplex virus 1 glycoprotein D (gD-1) as described previously 
(Berman et al., 1999; Rerks-Ngarm et al., 2009). 
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Immunoblots 
Growth conditioned cell culture supernatants with and without 25 mM DTT were 
analyzed for identity and molecular mass on 8–12% NuPage SDS-PAGE gel in MES 
running buffer and transferred to a PDVF membrane using standard protocol for iBlot 
(ThermoFisher Scientific, Waltham, MA). Membrane was blocked in 5% milk 
overnight on shaker at room temperature then washed 3 times with phosphate buffer 
saline with 0.01% Tween 20 (PBST; Sigma-Aldrich, St. Louis, MO) for 10 min. 
Membrane was probed with 5 µg/ml rabbit polyclonal anti-rgp120 antibody from 
previous immunization study (PB94)(Berman et al., 1999) in 5% milk for 2 h on 
shaker at room temperature, washed, then probed with 1:5,000 dilution of HRP-
conjugated anti-rabbit secondary antibody (Jackson ImmunoResearch, West Grove, 
PA) in 5% milk for 2 h on shaker at room temperature and washed again. Antibody 
was detected using WesternBright reagents (Advansta, Menlo Park, CA) and 
visualized using an Innotech FluoChem2 system (Genetic Technologies Grover, 
MO). 
 
Antibody Binding Assays 
A fluorescent immunoassay (FIA) was used to measure antibody binding. Briefly, 96 
well plates (Greiner, Bio-One, USA) were coated with 60 µl per well of 2 µg/ml of 
mouse anti-gD antibody (34.1) in phosphate buffer saline (PBS) overnight. Plates 
were blocked by adding 100 µl per well of 1% bovine serum albumin (BSA) in PBS 
on a shaker for 2 h at room temperature. Plates were then washed four times with 100 
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µl per well of PBST. Sixty microliter of supernatant was added and incubated 
overnight at 4°C then washed again. Serial 1:3 dilutions of monoclonal human 
antibody in PBS were added to each well and incubated for 90 min on a rocker at 
room temperature then washed again. Plates were then probed with 100 µl per well of 
Alexa Fluor 488 goat anti-human IgG secondary antibody (ThermoFisher Scientific, 
Waltham, MA) at a 1:5,000 dilution in 1% BSA PBS for 90 min on a rocker at room 
temperature then washed again. Antibodies were detected by adding 50 µl per well of 
PBS and visualizing at 495 nm. FIA was performed in triplicate. 
 
Virus Neutralization Assays 
Envelope gene sequences recovered from provirus clones were chemically 
synthesized de novo. Synthetic wild type (WT) non-codon-optimized gp160 gene 
sequences (Invitrogen Inc., Waltham, MA) were inserted into an in-house plasmid 
expression vector (pCF1) containing a CMV promoter using standard techniques. 
PCR site-directed mutagenesis was performed to create variants of gp160 using a 
standard protocol for Gibson Assembly (New England Biolabs, Inc, Ipswich, MA). 
Recombinant plasmid sequences were confirmed by Sanger sequencing (University 
of California Sequencing Facility, Berkeley, CA). DNA was extracted and purified 
with a maxiprep kit (Qiagen, Redwood City, CA). The plasmids were transferred to 
Monogram Biosciences (South San Francisco, CA) for testing in a pseudotype virus 
neutralization assay (PhenoSense®). The pseudotype viruses were tested for 
sensitivity and resistance to neutralization by antibodies in autologous 
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contemporaneous plasma, as well as a panel of broadly neutralizing antibodies 
provided by the NIH AIDS Reagent Program, Polymun Scientific (Vienna, Austria), 
and Dr. Dennis Burton (Scripps Clinic and Research Institute, La Jolla, CA). The 
neutralizing antibody titer (IC50) for monoclonal antibodies is defined as the 
concentration of purified mAb (µg/L) that produces a 50% reduction in target cell 
infection. 
 
Results 
Identification of a Treatment-Naïve Elite Suppressor With Neutralization 
Breadth 
Twenty-nine plasma specimens from ART-naïve individuals were obtained from the 
SCOPE Study cohort (University of California, San Francisco) and screened for 
neutralization breadth with a panel of 22 international virus isolates from five 
different genetic clades (Table 1.1). Twenty-five of the plasma specimens were from 
individuals previously identified as elite supressors (ESs) and four specimens were 
from normal progressors. One specimen from a normal progressor (Z23) from a 
different cohort previously identified as possessing broad and potent neutralizing 
antibodies was used as a positive control. The panel included 5 viruses reported by 
Simek et al. (Simek et al., 2009) previously used to screen for elite neutralizers. Two 
specimens isolated from elite suppressors, EN2 and EN3, were effective in 
neutralizing 17 or 18 of the 22 viruses in the panel (respectively). Based on this result 
and the availability of clinical specimens, we selected one individual (EN3) for 
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further study. EN3 is an African American woman who was 47 years old and HCV 
negative at the time of collection. Clinical data showed EN3 possessed < 75 HIV 
RNA copies/ml for over 4 years. Plasma from EN3 was tested against an expanded 
panel of viruses and was capable of neutralizing 69% of viruses tested from clades A, 
B, C, D, and AE, with some ID50 titers above 300 (Table 1.2). 
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Table 1.1. Screening of 25 Elite Suppressors and 4 Normal Progressors for 
Neutralization Breadth. 
 
Patient samples exhibiting control of virus replication without anti-retroviral therapy 
were obtained from the SCOPE cohort (University of California, San Francisco) and 
were screened using Monogram Biosciences’ PhenoSense® neutralization assay for 
breadth against a panel of 22 internationally recognized viruses. Each assay included 
acceptability criteria to ensure that inter-assay variation between IC50s, measured 
with reference standards, fell within 2.5-fold 95% of the time. The neutralizing 
antibody titer (IC50) is defined as the reciprocal of the plasma dilution that produces 
a 50% inhibition in target cell infection. Values in grey represent neutralization titers 
that are at least three times greater than those observed against the negative control 
(aMLV).  The clade B NL4-3 and JRCSF viruses were included as CXCR4- and 
CCR5-dependent positive controls, respectively. Z23 is a reference serum possessing 
broadly neutralizing antibodies. 
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Table 1.2. Expanded pseudovirus panel to define neutralization breadth in elite 
suppressor (EN3). 
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Phylogenetic Analysis of an Elite Suppressor and a Normal Progressor 
Illustrates Significant Difference in Genetic Variation 
Phylogenetic analysis compared proviral sequences isolated from the elite suppressor, 
EN3, and a normal progressor, EN1, which both possessed broadly neutralizing 
antibodies. These were analyzed with MEGA6 to generate a maximum likelihood tree 
using the General Time Reversible (Tamura et al., 2013) model with 1,000 bootstrap 
replicates. EN3 sequences had less intra-patient genetic variation compared to 
proviral sequences from EN1, who showed similar neutralization breadth (Fig 1.1). 
EN3 had 126 (4.8%) sites with polymorphisms whereas EN1 had 396 (14.8%) sites 
with polymorphisms. The result conformed to previous observations, reporting less 
genetic variation and slower viral evolution in an elite suppressor (EN3) compared to 
a normal progressor (EN1). 
 
 26 
 
Fig 1.1. Phylogenetic analysis of proviral sequences isolated from an elite 
suppressor (EN3) and a normal progressor (EN1) that both possess bNAbs. 
Proviral sequences were recovered from two individuals (EN1 and EN3) using the 
Monogram PhenoSense® assay system. Evolutionary analyses were conducted in 
MEGA6 using a Maximum Likelihood method with 1000 bootstrap replicates and a 
discrete Gamma distribution to model evolutionary rate. The tree is drawn to scale, 
with branch lengths measured in the number of substitutions per site. Sequences used 
in mutagenesis studies, EN3d071 and EN3c059, are shown with a black rectangle. 
 
 27 
Characterization of Proviral gp160 Sequences Isolated From EN3 
The physical characteristics of the gp160 sequences were analyzed for amino acid 
length, the number of cysteines, and location of potential N-linked glycosylation sites 
in each region (Table 1.3). Sequences were compared to the Los Alamos National 
Laboratory database (“HIV sequence database main page,” n.d.) filtered for clade B 
subtype envelope sequences, with one sequence per individual. EN3 had a 
significantly longer V1 region (37–39 amino acids; Kruskal-Wallis test, p < 0.0001) 
and rare cysteines in the V1 hypervariable region (3–4 cysteines; Kruskal-Wallis 
test, p < 0.0001) compared to the dataset from LANL (average V1 length is 27 amino 
acids; average number of cysteines in V1 is 2). When the recovered sequences were 
aligned (Fig 1.2), all of the sequences with the exception of clone d071 possessed two 
additional N-linked glycosylation sites and two extra cysteines (Cys) in the V1 
region. The extra Cys residues occurred at fixed locations (C134+1 and C136 using 
HXB2 numbering), resulting in a total of 20 Cys in the gp120 fragment compared to 
the normal 18 Cys typically found in the major (M) class of HIV envelope sequences. 
The EN3d071 Env possessed a Cys at position 134+1, like all of the other viruses 
from this individual, but had the polymorphism C136R, which is adjacent to a 15 
amino acid insertion between HXB2 positions 134 and 135 (Fig 1.2). 
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Table 1.3. Physical characteristics of 20 functional proviral sequences isolated 
from EN3. 
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Fig 1.2. V1/V2 regions of proviral sequences isolated from an elite suppressor 
(EN3). 
(A) Alignment of functional proviral sequences isolated from an elite suppressor 
(EN3). V1 region is defined as amino acids 131–157 and V2 region is defined as 
amino acids 158–196 using sequence numbering relative to HXB2 reference standard. 
Arrows above the alignment show the location of four beta strands described in 
McLellan et al. (McLellan et al., 2011). Black rectangles show the location of 
canonical cysteines in the V1/V2 region. Green rectangles show aberrant cysteines in 
functional sequences isolated from EN3. Blue rectangles show potential N-linked 
glycosylation sites that are part of the 13 or 15 amino acid insertion in V1. Residues 
circled in red were targeted in mutagenesis experiments. (B) Primary structure of 
EN3d071 wild type (WT) and mutants. Single point mutations of EN3d07 WT were 
introduced to create three different mutants of Env (EN3d071 C136A with no extra 
cysteines in V1, EN3d071 R(134+1)C with two extra cysteines in V1, and K170E 
with one extra cysteine in V1). Non-canonical cysteines are shown in red. K170E 
mutation is shown in blue. (C) Homology models of gp120s EN3d071 wild type 
(WT) and mutants. Homology models of EN3d071 C136A (18 cysteines), EN3d071 
WT (19 cysteines), EN3d071 R(134+1)C (20 cysteines), and EN3d071 K170E (19 
cysteines) were built using Modeller v9.21 with 5fykG template. V1 regions are 
shown in cyan. V2 regions are shown in gray. Cysteines located in the V1 region are 
shown in yellow. Polymorphisms are labeled with A136 shown in green, R(134+1) 
shown in orange, K170 shown in purple, and E170 shown in magenta. 
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Sensitivity to Neutralization by Polyclonal Antibodies in Autologous Plasma and 
Broadly Neutralizing Monoclonal Antibodies (bN-mAbs) 
Pseudotype viruses representing the 20 envelope clones from EN3 were constructed 
and tested for sensitivity to neutralization by contemporaneous autologous plasma 
and by a panel of prototypic bN-mAbs (Table 1.4). We observed that all viruses were 
sensitive to neutralization by autologous plasma (range 1:322–1:53,788) with a mean 
neutralization titer of 1:3,376. However, one clone, EN3c059, was exceedingly 
sensitive to neutralization by autologous plasma with a neutralization titer of 
1:53,788. We observed that this clone was also particularly sensitive to neutralization 
by the positive control Z23. 
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Table 1.4. EN3 pseudotype virus neutralization titers from autologous sera and a 
panel of bN-mAbs. 
 
 
 
When we examined the sensitivity of the EN3 viruses to prototypic bN-mAbs, 
we found that all but clone EN3d071 were resistant to neutralization by the PG9 and 
PG16 broadly neutralizing monoclonal antibodies (bN-mAbs) known to bind to 
glycan-dependent epitopes in the V1/V2 domain (McLellan et al., 2011). When we 
examined the sensitivity of these Envs to bN-mAbs that recognized glycan-dependent 
epitopes at the base of the V3 domain (Pejchal et al., 2011), we found that all of the 
clones were sensitive to neutralization by the PGT128 bN-mAb but all of the clones 
were resistant to neutralization by the PGT121 bN-mAb. We found that 18 of 20 
clones were sensitive to neutralization by the VRC01 bN-mAb specific for the CD4-
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binding site, and the PGT145 bN-mAb that recognizes a trimer-specific epitope 
involving the V1/V2 domain. In addition, 15 of 20 clones were sensitive to 
neutralization by the 4E10 bN-mAb specific for the membrane proximal external 
domain (MPER). Finally, 5 of 20 clones were sensitive to the 35022 bN-mAb specific 
to the gp120 and gp41 interface. 
 
Effect of Extra Cysteine Residues and Polymorphisms at Positions 130 or 170 on 
Sensitivity to Neutralization by bN-mAbs 
Because the EN3d071 clone was the only envelope with 19 Cys residues and the only 
virus that was sensitive to neutralization by the PG9 and PG16 bN-mAbs, we carried 
out mutagenesis studies to examine the effect of 18, 19, and 20 Cys residues on virus 
infectivity and sensitivity to neutralization. In addition to lacking C(134+1), 
EN3d071 is the only sequence that had a lysine (K) at position 170 where the other 19 
sequences had a glutamic acid (E) at this position (Fig 1.2). Previous studies have 
suggested that K170 can be important for PG9 binding (Doria-Rose et al., 2012). To 
examine potential effects of the aberrant V1 cysteines and K170, we used site-
directed mutagenesis to create three variants of EN3d071 gp160. These included: (1) 
the EN3d071 C136A variant with 18 cysteines in gp120, (2) the EN3d071 R(134+1)C 
with 20 cysteines in gp120, and (3) the EN3d071 K170E variant with 19 cysteines in 
gp120 (Fig 1.2). The wild type and mutated gp160 genes were then used to create 
pseudoviruses and tested for sensitivity to neutralization by a panel of bN-mAbs, 
including PG9, and autologous sera. 
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When expressed as pseudoviruses, we found that the wild type (WT) 
EN3d071 Env (19 Cys in gp120) and the EN3d071 C136A variant (18 Cys in gp120) 
retained infectivity and both possessed the CCR5 chemokine receptor (R5) tropic 
phenotype (Table 1.5). In contrast, the R(134+1)C variant (20 Cys in gp120) that 
contained two non-canonical cysteines was non-infectious. When the 19 Cys variant 
possessing the K170E variant was examined, we observed that it had reduced 
infectivity but still retained the R5 receptor phenotype. 
 
Table 1.5. Infectivity of wild type and mutant EN3d071 pseudoviruses. 
 
 
We next examined the sensitivity to neutralization by autologous plasma, and 
the panel of bN-mAbs directed to different epitopes (Table 1.6). The loss of the 
cysteine in EN3d071 C136A may have increased resistance to neutralization by 
VRC01 but the difference in IC50 values is within the margin of error. The K170E 
mutation caused resistance to neutralization by PG9 and PG16 and surprisingly 
increased sensitivity to 4E10. Neutralization sensitivity to the PGT145, PGT128, 
35022 bN-mAbs, and autologous plasma was preserved in all testable variants. 
 
 35 
Table 1.6. EN3 wild type and mutant pseudoviruses sensitivity to neutralization 
by bN-mAbs and autologous sera. 
 
 
 
The EN3c059 clone was highly sensitive to neutralization by 
contemporaneous autologous sera (ID50 above 53000) and differed by only 3 point 
mutations, E32Q, N130D, and A533V from the EN3 consensus sequence. We 
wondered if the N130D polymorphism, which eliminates a potential N-linked 
glycosylation site, could account for the increased neutralization sensitivity of this 
variant. We used site-directed mutagenesis to express EN3c059 WT and a variant 
with the D130N mutation (EN3c059 D130N) and tested for sensitivity to 
neutralization by a panel of bN-mAbs and autologous sera. Surprisingly, we found 
that the D130N polymorphism did not affect sensitivity to neutralization by 
contemporaneous autologous sera (Table 1.6). 
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Effect of Extra Cysteine Residues and K170E on bN-mAb Binding to gp120 
Additional studies were carried out to characterize bN-mAb binding to recombinant 
gp120s derived from EN3 envelope proteins. Because multiple bN-mAbs recognize 
epitopes that are dependent on mannose-5 (Man5) for binding, the Envs were 
expressed in HEK293 cells lacking N-acteylglucosaminyl transferase 1 (HEK293S 
GnTI- cells). The absence of N-acetylglucosaminyl transferase 1 disrupts the 
glycosylation pathway, resulting in the production of monomeric gp120s that contain 
a high mannose (Man5) glycan found on native HIV virions. The recombinant 
proteins predominately migrated as monomeric proteins and were not degraded by 
proteolysis often observed for Envs from clade B viruses (Fig 1.3). The EN3d071 
R(134+1)C variant expressed well even though the pseudotype viruses made with this 
envelope were not infectious. 
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Fig 1.3. HEK293 GnTI- expression of recombinant gp120 EN3d071 WT and 
mutants. 
Recombinant gp120 sequences EN3d071 C136A (18 cysteines), EN3d071 WT (19 
cysteines), EN3d071 R(134+1)C (20 cysteines), and EN3d071 K170E (19 cysteines) 
were transiently transfected in HEK293 GnTI- cells. HEK293 GnTI- cells lack N-
acetylglucosaminyltransferase 1, disrupting the glycosylation pathway and resulting 
in Man5 glycans which have a smaller molecular weight. Supernatant with and 
without 25 mM DTT was run on SDS-PAGE gel, transferred to a PDVF membrane, 
and probed with purified rabbit polyclonal anti-gp120 antibodies (PB94) from a 
previous immunization study. EN3d071 WT and mutants showed similar expression 
levels with a small amount of aggregation detected in unreduced samples. 
 
A fluorescence immunoassay (FIA) was used to characterize the binding of a 
panel of bN-mAbs to immunoaffinity purified variants of the EN3d071 Env protein. 
We found that the envelopes with 18, 19, and 20 cysteines all bound to PG9, 
PGT128, and VRC01 and did not bind to PGT121 (Fig 1.4). They also did not bind to 
PG16, which was expected because the gp120s were monomeric and lacked the 
hybrid complex glycans required for PG16 binding (McLellan et al., 2011). Thus, all 
three proteins possessed the epitopes recognized by the PG9, PGT128, and VRC01 
bN-mAbs but lacked the epitopes recognized by the PG16 and PGT121 bN-mAbs. 
 38 
EN3 K170E had a similar binding profile but did not bind to PG9. This provides 
additional evidence that the inability of PG9 to neutralize 19 of the 20 Envs recovered 
from EN3 appear to be attributable the E170K polymorphism in the V2 region rather 
than the extra pair of Cys residues in the V1 region. 
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Fig 1.4. bN-mAb binding to recombinant gp120 EN3d071 WT and mutants by 
fluorescent immunoassay. 
Recombinant gp120 sequences EN3d071 C136A (18 cysteines), EN3d071 WT (19 
cysteines), EN3d071 R(134+1)C (20 cysteines), and EN3d071 K170E (19 cysteines) 
were produced with an N-terminal gD tag and captured onto microtiter plates with a 
mouse monoclonal anti-gD antibody. The captured proteins were then incubated with 
a panel of broadly neutralizing monoclonal antibodies that included PG9, PGT121, 
PGT128, and VRC01. After washing, the wells were incubated with Alexa Fluor 488 
labeled goat anti-human IgG (ThermoFisher Scientific, Waltham, MA) and washed as 
described in Materials and Methods. 
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Discussion 
In this paper, we have analyzed proviral Env sequences from a rare elite suppressor 
(EN3) with the bNAb/ES phenotype. As reported in previous studies (Bailey et al., 
2006; Bello et al., 2007, 2004; Casado et al., 2010; Lassen et al., 2009; Roy et al., 
2017; Sandonís et al., 2009; Scutari et al., 2018; Smith et al., 2013; Wang et al., 
2003), we found that proviral sequences from EN3 were highly homogeneous 
compared to proviral sequences recovered from a normal progressor. This result 
supports the idea that virus evolution is slower in ENs due to a reduced rate of virus 
replication. Because of this slow rate of virus evolution, we reasoned that it might be 
easier to recover Envs more closely related to those that elicited bNAb from 
individuals with the bNAb/ES phenotype than from normal progressors that exhibit 
much higher levels of proviral Env sequence diversity. Moreover, we postulated that 
analysis of sequences from individuals with bNAb/ES phenotype might provide clues 
regarding structural features that enhance for the formation of bNAbs compared to 
Envs from normal progressors that exhibit higher levels of virus diversification. The 
possibility that HIV has evolved structural features to modulate the immunogenicity 
of epitopes recognized by bNAbs is well supported by the unusually high degree of 
N-linked glycosylation resulting in a “glycan shield” (Wei et al., 2003), indels 
(insertions and deletions) in variable regions (Pinter et al., 2004), and the observation 
that cleavage sites for antigen processing enzymes occur in close proximity to 
epitopes recognized by bNAbs (Yu et al., 2010). 
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In the present study, we found that Envs sequences recovered from EN3 were 
highly homogenous (99.1% pairwise identity) and 19 of 20 sequences displayed an 
unusual insertion in the V1 region that added a pair of extra cysteine residues, which 
may form an extra disulfide bond, and two additional N-linked glycosylation sites. 
The V1 region has long been known to be highly immunogenic and has previously 
been termed the “global regulator” of neutralization sensitivity (Pinter et al., 2004). It 
is the first target of autologous neutralizing antibodies (Granados-Gonzalez et al., 
2009; Rong et al., 2009, 2007; Walker et al., 2010). Evolution of glycosylation sites 
in the V1 region is thought to be a key factor in driving the evolution of bNAbs that 
normally occurs 2 years or more post infection (Chackerian et al., 1997; Frost et al., 
2005; Moore et al., 2009; Rong et al., 2007; Sagar et al., 2006; Wei et al., 2003). 
Additionally, the V1 region is located at the apex of the virus spike and is in close 
proximity to several epitopes recognized by bNAbs (McLellan et al., 2011; Simek et 
al., 2009; Walker et al., 2009). Based on these observations, the three changes we 
have documented in the V1 region are all features of the type expected to affect either 
the antigenic structure or the immunogenicity of the Env protein. 
In principle, 19 of 20 Envs from this individual could form 10 disulfide 
bridges compared to the 9 disulfide bridges found in most gp120 sequences. HIV-1 
gp120 has 18 conserved cysteines that form 9 disulfide bridges present in all 
published crystal structures. Approximately 7% of clade B viruses from newly 
infected individuals also have 20 cysteines (Jobes et al., 2006) and 5.5% of clade B 
viruses have 2 extra cysteines in the variable 1 (V1) region (van den Kerkhof et al., 
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2016). The EN3d071 sequence was unusual in that it possessed only 19 Cys and 
therefore contained an unpaired Cys that could only form 9 disulfide bridges. Free 
Cys residues are unusual in most secreted proteins and often lead to the formation of 
dimers or aggregates. The prevalence of these extra cysteines raised the possibility 
that EN3 envelope proteins might provide a functional advantage perhaps related to 
enhanced virus infectivity, neutralization escape, or increased immunogenicity. 
Additionally, they provided for the possibility of rearrangements of disulfide 
structures. 
Additional N-linked glycosylation sites and insertions in the V1/V2 domain 
are well documented immune escape mechanisms known to prevent the binding of 
bNAbs (Chackerian et al., 1997; Frost et al., 2005; Moore et al., 2009; Rong et al., 
2007; Sagar et al., 2006; Wei et al., 2003). Surprisingly, neither the extra 
glycosylation sites, the 13 amino acid insertion, nor the extra cysteines in the V1 
region affected binding or sensitivity to neutralization by bN-mAbs PG9, PG16, 
PGT121, PGT128, PGT130, 35022, or 4E10. Therefore these changes may have 
evolved to serve another function, perhaps related to virus infectivity or stability. 
When this possibility was considered, it was interesting that the R(134+1)C variant of 
EN3d071, possessing 20 Cys residues, had little or no infectivity compared to the WT 
Env that possessed 19 Cys. All other clones possessing 20 Cys and the C(134+1) 
polymorphism were infectious, indicating epistatic mutations are required to 
compensate for the presence of the additional Cys. Similarly, the K170E variant of 
EN3d071 had reduced infectivity, despite the presence of E170 in all other clones. 
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Thus, epistatic mutations are also required to preserve infectivity for the K170E 
polymorphism. Two of the four point mutations altering amino acids to match the 
consensus sequence reduced infectivity, perhaps indicating the fitness landscape is 
restricted. 
Although we did observe a mutation that improved sensitivity to 
neutralization by PG9 binding, this mutation occurred in only one virus clone and was 
distinct from the insertion in the V1 region found in the 19 other viruses. The 
glutamic acid (E) at position 170 accounts for the resistance to neutralization by the 
PG9 bN-mAb in all of the viruses except EN3d071 that possesses a lysine (Lys) at 
this position. Previous studies reported that the K168E, K169E, and K171E 
polymorphisms disrupt PG9 binding and cause resistance to neutralization by PG9. 
This is likely due to the change in charge on the “C” beta strand in the V2 region, 
which is part of the PG9 epitope (McLellan et al., 2011). It is consistent that K170E, 
located on the “C” beta strand, also disrupts binding and confers resistance to 
neutralization by PG9. 
Based on these studies, the possibility remains that the insertion in the V1 
region, the extra pair of cysteines, and the extra glycosylation sites may have 
contributed to the formation of bNAbs in EN3. It is important to note that the gp160 
sequences studied here are a sample of the virus population taken at a single time 
point and may not include the actual viral sequences that stimulated the production of 
the bN-mAbs in contemporaneous plasma. However, variation within the 20 proviral 
sequences was minimal, supporting previous reports suggesting that viral evolution 
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may be slower in this elite suppressors (Bello et al., 2007, 2004; Casado et al., 2010; 
Okulicz et al., 2009; Pereyra et al., 2008; Roy et al., 2017; Sandonís et al., 2009; 
Scutari et al., 2018; Smith et al., 2013; Wang et al., 2003). These sequences may be 
more similar to their bN-mAb-inducing predecessor than viruses recovered from 
normal progressors, and thus better vaccine candidates. The envelopes described in 
this paper provide the basis for future immunization studies where the immunologic 
potential of individuals possessing the rare bNAb/ES phenotype can be examined in 
greater detail. To this end, efforts are in progress to create trimeric gp140s and DNA 
vectors as well as the monomeric gp120s described in this paper to further define the 
immunogenic properties of these Env proteins. 
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Abstract 
A major goal in HIV vaccine research is to identify envelope glycoproteins (Envs) 
capable of eliciting broadly neutralizing antibodies (bNAbs) similar to those found in 
rare individuals termed elite neutralizers (ENs). To this end, we are studying Envs 
derived from an unusual subgroup of ENs that control viral load without antiretroviral 
therapy (ART). Since Env diversity is often limited in controllers, we reasoned that 
Envs from individuals with the unusual EN/controller phenotype might have retained 
immunogenic features that promoted the induction of bNAbs and other effective 
antiviral immune responses. In a cohort of 53 ART-naïve African American women 
exhibiting varying levels of HIV control, 11 controllers were found to have bNAb 
activity. An EN with viremic control for over 17.5 years was selected for further 
characterization. Plasma virus sequences collected several years after infection coded 
for functional Envs with only 17 potential N-linked glycosylation sites (PNGS) in the 
gp120 sequence compared to the normal 26 PNGS. Pseudovirus and recombinant 
gp120 of a low PNGS Env were prepared to investigate antigenic structure and 
immunogenic potential. This minimally glycosylated immunogen possessed multiple 
epitopes recognized by broadly neutralizing monoclonal antibodies including those 
targeting the V1/V2-domain (PG9 and PG16) and the CD4-binding site (VRC01). 
Monomeric gp120 was administered to rabbits and compared to MN gp120, 
previously used in the RV144 clinical trial. The low PNGS Env elicited an improved 
cross-clade tier-1 neutralizing response with increased binding to linear epitopes in 
the V3 region. Our results suggest that Envs found in this individual may have 
 48 
contributed to the formation of bNAbs by creating glycan holes that exposed regions 
of the Env surface normally occluded by the glycan shield. These studies provide the 
foundation for additional immunologic studies of naturally occurring Envs with 
minimal glycosylation. 
 
Introduction 
The global pandemic of HIV/AIDS continues to be a significant global health crisis 
and remains the leading cause of death among women of reproductive age (15 – 49 
years old)(UNAIDS, 2019b). In the United States, few studies have focused on 
viruses and immune responses in African American women who represent the most 
prevalent high-risk group outside of men who have sex with men (CDC, 2018). While 
HIV transmission can now be prevented with pre-exposure prophylaxis 
(PreP)(Rodger et al., 2019), persistent disparities across the continuum of care make a 
prophylactic vaccine necessary for the eradication of HIV/AIDS and research efforts 
should focus on the most affected communities (Fauci, 2017). Here, we introduce a 
study focused on 53 HIV-positive African American women. 
A primary goal of HIV-1 vaccine design is the development of an 
immunogenic envelope glycoprotein (Env) able to elicit protective immune 
responses, including broadly neutralizing antibodies (bNAbs). This has proved a 
formidable challenge due to the extraordinary diversity of env, which is attributable 
to HIV’s error-prone reverse transcriptase, frequent recombination events, and the 
preservation of viral variants in the host genome (Chun et al., 1997; Preston et al., 
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1988; Zhang et al., 2010). The Env spike mediates attachment and entry into the host 
cell and is a trimer of heterodimers. The env gene is transcribed as a precursor 
protein, envelope glycoprotein 160 (gp160), which is then cleaved into two subunits, 
glycoprotein 41 (gp41) and glycoprotein 120 (gp120)(Moulard and Decroly, 2000). 
The extracellular subunit, gp120, possesses an average of 26 N-linked glycans (Cao et 
al., 2018). The dense packing of host-derived glycans constitutes a glycan shield that 
protects functionally important regions of gp120 from recognition by the humoral 
immune system. Insertions and deletions as well as shifts in the location of 
glycosylation sites provide an additional mechanism of antigenic variation (Behrens 
et al., 2016; Lasky et al., 1986; Wei et al., 2003). Despite these challenges, bNAbs 
eventually develop in a fraction of HIV-positive individuals, often targeting glycans 
at conserved locations which initially evaded immune recognition (Doria-Rose et al., 
2009; Hraber et al., 2014; Julien et al., 2013b; McLellan et al., 2011; Pejchal et al., 
2011; Walker et al., 2009; Zhou et al., 2010). Because bNAbs typically develop two 
years post infection and viral evolution typically outpaces the contemporaneous 
antibody response, the production of bNAbs does not correlate with improved disease 
outcomes (Bhiman et al., 2015; Bonsignori et al., 2016; Doria-Rose et al., 2014; Euler 
et al., 2010; Freund et al., 2017; Wu et al., 2010; Zhou et al., 2013). However, passive 
immunization studies in nonhuman primates have demonstrated that bNAbs can 
provide protection if present prior to infection (Baba et al., 2000; Hessell et al., 2010, 
2009; Mascola et al., 2000, 1999; Moldt et al., 2012; Parren et al., 2001; Shibata et 
al., 1999). 
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 There has been substantial effort to design Envs capable of eliciting the 
production of bNAbs. Native-like trimers have been engineered with antigenic 
structures recognized by the major classes of bNAbs, i.e., those that target V2-
glycans, V3-glycan supersite, CD4-binding site, membrane proximal external region 
(MPER), and gp120-gp41 interface (Julien et al., 2013a; Sok and Burton, 2018). 
However, these trimers have so far failed to consistently elicit the production of 
bNAbs in immunization studies (Landais et al., 2016). From these studies, it is clear 
that while it is now possible to create a variety of recombinant Envs that possess the 
epitopes recognized by bNAbs, these epitopes are poorly immunogenic. This may 
resemble the situation that occurs in natural infection where most people are infected 
with viruses possessing the epitopes recognized by bNAbs but few people actually 
make these antibodies (Simek et al., 2009). 
One current vaccination strategy to improve Env immunogenicity and direct 
the antibody response to sites of vulnerability is to remove and alter the location of 
PNGS (Crooks et al., 2017; Dubrovskaya et al., 2019; Klasse et al., 2018; Li et al., 
2008; Ringe et al., 2019; Zhou et al., 2017). Previous studies have demonstrated that 
the deletion of PNGS can improve immunogenicity (Back et al., 1994; Crooks et al., 
2015; Koch et al., 2003; Li et al., 2008; Liang et al., 2016; McCaffrey et al., 2004; 
Pancera et al., 2014; Wang et al., 2015; Zhou et al., 2017) with one study showing 
ID50s proportional to the exponential surface area of accessible polypeptide (Zhou et 
al., 2017). Neutralizing antibodies often target glycan holes and the introduction of 
PNGS can confer resistance (Crooks et al., 2017; Klasse et al., 2018; Ringe et al., 
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2019; Wagh et al., 2018). Envs have been engineered with PNGS introduced at 
immunodominant regions and removed at other locations in order to re-direct 
neutralizing antibodies to the CD4-binding site (Crooks et al., 2017; Klasse et al., 
2018; Ringe et al., 2019). Based on these studies, deglycosylated Env trimers have 
been used in rabbits to prime the immune system, increasing the initial neutralizing 
antibody response, followed by boosts that introduce PNGS, in an effort to direct 
neutralizing antibodies to sites of vulnerability (Dubrovskaya et al., 2019). This 
mirrors the course of natural infection, where early transmitter/founder (T/F) viruses 
typically have fewer PNGS and viruses evolve additional PNGS over time to escape 
immune selection pressure (Chohan et al., 2005; Dacheux et al., 2004; Derdeyn et al., 
2004; Keele et al., 2008; Liu et al., 2011; Moore et al., 2012). This pattern has also 
been observed in longitudinal studies examining the co-evolution of viral population 
and bNAb maturation, with the introduction of PNGS as a common mode of viral 
escape (LaBranche et al., 2018). Thus, less glycosylation not only increases 
immunogenicity, they may also mimic the T/F phenotype and Envs that engage with 
germline bNAb precursors. 
It is important to note that few of the vaccine immunogens used to date were 
derived from people who made bNAbs, and those that have been made, were derived 
from people who exhibited normal disease progression (Landais et al., 2016). In this 
study, we have begun to characterize Envs from rare individuals who possessed 
bNAbs and developed effective antiviral immune responses. Using these Envs, we 
examine if they have incorporated yet to be defined structural features that affect the 
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formation of effective humoral and cellular immune responses. In principal, such 
features may enhance immune recognition through exposure to regions normally 
shielded from the immune system by glycosylation or conformational masking, 
increase susceptibility or resistant to proteases that mediate antigen processing and 
presentation, or modulate binding to co-receptors such as a4b7 or DC-SIGN that 
facilitate interactions with antigen presenting cells (e.g. follicular dendritic 
cells)(Cicala et al., 2009; Geijtenbeek et al., 2000; Kwong et al., 2002; López et al., 
2000). 
Here, we examine Envs derived from an individual with the rare EN/controller 
phenotype, i.e., produced potent bNAbs (elite neutralizer or EN) and controlled viral 
load in the absence of antiretroviral therapy (ART). This individual was identified in 
the course of a study of 53 HIV-positive African American women who exhibited 
varying levels of viral control without ART. We found that 26% were capable of 
neutralizing pseudoviruses from four out of five clades tested. Of these, one viremic 
controller possessing particularly potent bNAbs, EN6, was selected for additional 
characterization. Envs from this individual possessed two unusual structural features 
that may have contributed to the development of protective antibody responses. The 
plasma viruses were remarkable in that they possessed 35% fewer PNGS than most 
other reported gp120s. Additionally, proviral Env had elongated V1/V2 regions with 
two additional non-conserved cysteine residues, potentially able to form unusual 
disulfide loops. Both plasma and proviral Envs were infectious in pseudotype assays 
and possessed multiple epitopes recognized by bN-mAbs. A minimally glycosylated 
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recombinant gp120 was expressed in a cell line that restricted N-linked glycosylation 
to high-mannose glycoforms and purified protein was used in rabbit immunization 
studies. These studies are consistent with the possibility that Envs from individuals 
with the EN/controller phenotype have unusual structural features that may have 
affected the quality and specificity of the protective immune response. 
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Results 
Identification of five elite neutralizers  
Data provided by the WIHS cohort (Bacon et al., 2005; Barkan, 1998) was used to 
identify HIV-positive, ART-naïve African American women exhibiting some level of 
virus control. Forty-three individuals were selected with periods of virus control in 
longitudinal studies that lasted 3 – 17.5 years (µ = 12 years). These were divided into 
two clinical categories, elite controllers (n = 28) and viremic controllers (n = 15), 
based on viral loads (<100 RNA copies per ml or 100 – 1,000 RNA copies per ml, 
respectively). Additionally, we selected a control group of ten individuals including 
long-term non-progressors (no periods of viral control and >500 CD4+ cells per ml 
for 7+ years; n = 4), and normal progressors (n = 6). From each individual, plasma 
samples from two visits were screened for neutralization potency and breadth against 
a standard panel of five viruses representing international strains routinely used to 
screen for elite neutralizers (Simek et al., 2009)(S1-S4 Tables). Sera from 26% of 
individuals were capable of neutralizing at least four out of five viruses in the initial 
screening panel (two elite controllers, nine viremic controllers, one long-term non-
progressor, and two normal progressors). On average, elite controllers had 
significantly lower neutralization titers and neutralization breadth compared to 
viremic controllers (p = 0.0004, Mann-Whitney U = 454; p < 0.0001, Mann-Whitney 
U = 425.5) and normal progressors (p = 0.0132, Mann-Whitney U = 184; p = 0.0021, 
Mann-Whitney U = 154.5)(Table 2.1). 
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Table 2.1. Neutralization potency and breadth of 53 HIV-positive ART-naïve 
African American women by clinical category. 
Neutralization potency and breadth were determined by neutralization titers at two 
time points assayed against the Simek panel of five pseudotype viruses (Simek et al., 
2009). Neutralization potency was defined as the geometric mean of ID50 titers. 
Neutralization breadth was defined as the arithmetic mean of the percentage of 
pseudoviruses neutralized at each visit. Bold values indicate statistically significant 
differences in neutralization potency and breadth in elite controllers. 
 
 
Plasma from the five individuals with the highest neutralization potency and breadth 
(geometric mean of ID50s > 150 1/dilution; neutralized ≥ 80% of viruses tested) were 
selected for additional characterization. One sample from each individual was 
assayed against an expanded panel of 22 viruses. All five samples were capable of 
neutralizing clade A, B, C, D, and CRF01_AE viruses (Table 2.2A). Of these, plasma 
identified as EN6 had the highest neutralization titers, with an average ID50 > 430 
1/dilution for all five clades and neutralized 100% of viruses tested (Table 2.2B). 
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Table 2.2 Identification of individuals with high levels of neutralizing antibodies 
found in cohort of HIV controllers. 
Bold indicates neutralization titers with at least 50% inhibition and three-fold greater 
than the specificity control (aMLV). (A) Neutralization titers from four viremic 
controllers (VC) and a normal progressor (NP) screened against two panels of 
pseudoviruses. Average titers for positive control viruses (JRCSF and NL4-3) and 
specificity control virus (aMLV) are shown for each panel with corresponding labels. 
The far-right column shows average titers of positive control plasma, Z23. (B) The 
results from both pseudovirus panels are summarized. 
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Unusual features in functional gp160 sequences from a viremic controller with  
elite neutralizing activity (EN6) 
The most potent neutralizer from the cohort, EN6, was selected for further analysis. 
An env library was generated from EN6 samples, expressed as pseudoviruses, and 
screened for infectivity. Full-length envs from 10 plasma-derived and 10 PBMC-
derived functional pseudoviruses were sequenced. All sequences were confirmed to 
be clade B by the Recombinant Identification Program (RIP) HIV clade assignment 
tool (Siepel et al., 1995). Envs were assayed to determine coreceptor usage; all 10 
proviruses and 3 plasma viruses were R5-tropic, while the remaining 7 plasma viruses 
were dual-tropic. 
The amino acid sequence length, cysteine content, and number of potential N-
linked glycosylation sites (PNGS) were determined for each region of gp160 and 
compared to Los Alamos National Laboratory Clade B reference sequences (Table 
2.3). Strikingly, the V1 regions were highly unusual in both the provirus sequences 
and the plasma virus sequences. All provirus sequences had an unusually long V1 
region containing two non-canonical cysteines, features found in only 7.4% and 6.7% 
of LANL clade B reference sequences, respectively. Proviral sequences had a 15 
amino acid insert that introduced two cysteines and four PNGS, while all plasma 
sequences lacked this insert (Fig 2.1). 
The most unusual finding was observed in plasma virus sequences, which had 
very low numbers of PNGS. The plasma virus sequences had only one PNGS (out of 
an expected four PNGS) in the V1 region at position 156 (Fig 2.1; Table 2.3). Plasma 
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virus also had fewer than average PNGS in C1, C2, C3, and V5 regions, resulting in a 
total of 17 PNGS in gp120 and 23 PNGS in gp160 (Fig 2.1; Table 2.3). Only three of 
the 1,936 (0.0015%) Clade B reference sequences had the same or fewer PNGS in the 
V1 region, gp120, or gp160, demonstrating the minimal number of PNGS in EN6 
plasma virus sequences is an exceptionally rare finding. 
The location of PNGS in plasma virus included key residues targeted by 
potent bN-mAbs in the V1/V2 region (N156 and N160) and the V3 region (N301 and 
N332)(McLellan et al., 2011; Pejchal et al., 2011; Walker et al., 2011; Zhou et al., 
2010). In addition, plasma viruses had PNGS at position 241 and 289, which have 
been engineered into Envs in multiple rabbit and macaque studies (Klasse et al., 
2018; McCoy et al., 2016; Ringe et al., 2019). Glycan holes at positions 241 and 289 
can elicit a strain-specific immunodominant response and introducing PNGS at these 
locations has re-directed the antibody response to sites of vulnerability (Klasse et al., 
2018; McCoy et al., 2016; Ringe et al., 2019). PNGS were absent at residue 360, 
proximal to the CD4-binding site, which has been shown improve immunogenicity 
(Crooks et al., 2017; Dubrovskaya et al., 2019; Zhou et al., 2017).  
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Table 2.3. Physical characteristics of functional proviral and plasma gp160 
sequences isolated from EN6. 
The number of amino acids, potential N-linked glycosylation sites (PNGS), and 
cysteines were counted in each region of functional gp160 sequences isolated from 
EN6 PBMC and plasma samples. Location of PNGS was defined as the location of N 
in NX(S/T) motif (where X is any amino acid except proline). The distribution of 
each measure was compared to clade B sequences from the Los Alamos National 
Laboratory 2017 Filtered Web Alignment. 
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Fig 2.1. Location of potential N-linked glycosylation sites and non-canonical 
cysteines in EN6. 
(A) Schematic shows position of potential N-linked glycosylation sites using aligned 
provirus and plasma virus consensus sequences. Select asparagine locations are 
labeled using HXB2 reference numbering. Variable and constant regions are also 
shown for reference. (B) Alignment of the V1 region of functional provirus and 
plasma virus Envs from EN6 samples. Non-canonical cysteines are highlighted in 
grey and PNGS are shown in black. EN6_226, shown in bold, was expressed and 
used as a rgp120 immunogen in this study. (C) Structure prediction models indicating 
exposed and glycosylated surfaces of gp120 in trimeric Env proteins. Homology 
models of gp120 for provirus and plasma virus consensus sequences were built using 
Modeller v9.21 (Webb and Sali, 2016) with PDB ID 5aco template (Pancera et al., 
2014) and N-linked glycans were added with GLYCAM Web Glycoprotein Builder 
(Woods Group, 2005). Surfaces occupied by N-linked glycans are shown in light 
grey; exposed rgp120 residues are shown in blue; CD4-binding site is shown in 
orange.  
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Sensitivity and resistance to neutralization of EN6-derived Envs by autologous  
plasma and bN-mAbs 
Envs derived from PBMCs and plasma were used in a recombinant pseudovirus assay 
to assess sensitivity and resistance to neutralization by polyclonal antibodies in 
autologous plasma and prototypic bN-mAbs. Both proviral and plasma viral Envs, 
with the notable exceptions of EN6_226 and EN6_031, were resistant to 
neutralization by contemporaneous plasma (Table 2.4; Fig 2.2A). Both the prototypic 
elite neutralizer plasma (Z23) and EN6 sera were unable to neutralize all but one of 
the EN6 proviral Envs with the V1 insert (Table 2.4; proviral). However, the Z23 
plasma differed from the EN6 plasma in that it was effective in neutralizing 9 of 10 
plasma viruses whereas only 2 were weakly neutralized by autologous plasma. This 
result suggests that the shorter V1 domain and the lack of PNGS facilitated 
neutralization by the Z23 plasma. The lack of neutralization by the EN6 plasma 
appears to reflect the evolution of viruses resistant to autologous neutralization as has 
been described previously (Euler et al., 2010; Frost et al., 2005; Richman et al., 
2003).  
When the sensitivity to neutralization by bN-mAbs was examined (Fig 2.2), 
the plasma viruses with the low numbers of PNGS and lacking the V1 insertion were 
markedly more sensitive to neutralization by the PG9, PG16, and VRC01 bN-mAbs 
compared to provirus (Fig 2.2B). Conversely, the provirus sequences were 
significantly more sensitive to neutralization by 2F5 bN-mAb targeting the MPER 
domain in gp41, which correlates with the polymorphism of A667E/G in the 2F5 
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epitope (Ofek et al., 2004). In control experiments, all of the viruses were found to be 
sensitive to the antiviral drug Fuzeon (enfuvirtide). 
Most EN6 Envs were resistant to neutralization by PGT121 and PGT128, 
despite having glycosylation at key residues in the V3 region, N332, N301, and 
IGDIR323-327 (Pejchal et al., 2011). Plasma Envs are likely resistant to neutralization 
by PGT121 and PGT128 due to polymorphism E(321+1)R, which substituted into a 
PGT128-gp120 crystal structure (PDB 5C7K) introduces a charge repulsion and steric 
hindrance with heavy chain residue R100 (Kong et al., 2015). While proviral Envs 
have E(321+1), they also have a 15 amino acid insert and five additional PNGS in the 
V1 region which have been shown to alter binding to PGT121 and PGT128 (Garces 
et al., 2014; Sok et al., 2014). The approach angle of PGT128 allows for better 
accommodation of V1 glycans (Kong et al., 2015; Pejchal et al., 2011). In contrast, 
V1 glycans, such as N137, have been shown to interfere with PGT121 binding 
(Garces et al., 2014). Thus, it is unsurprising that proviral Envs are resistant to 
neutralization by PGT121 but show modest sensitivity to PGT128. 
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Table 2.4. Sensitivity of EN6 Envs to neutralization by polyclonal antibodies in 
autologous plasma and broadly neutralizing monoclonal antibodies. 
Envs recovered from EN6 PBMCs and plasma were used to make pseudoviruses and 
tested for sensitivity to neutralization by autologous plasma and a panel of prototypic 
bN-mAbs. Neutralization titers represent the reciprocal of the plasma dilution (ID50) 
or monoclonal antibody concentration (IC50) with 50% inhibition and three-fold 
greater than the specificity control (aMLV) are shown in bold. A standard reference 
plasma with broadly neutralizing antibodies, Z23, is included as a positive control. 
Controls for each assay are shown at the bottom of the table. Coreceptor usage was 
determined for each Env-recombinant pseudovirus and shown in the second column. 
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*Maximum VRC01 concentration was 10 µg/ml (all other mAbs assayed up to 25 µg/ml) 
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Fig 2.2. Comparison of EN6 provirus and plasma virus sensitivity to 
neutralization by autologous sera and bN-mAbs. 
Comparison of provirus and plasma virus EN6 clones to neutralization by (A) 
autologous plasma (ID50) and (B) bN-mAbs (IC50). Graphs are organized in rows by 
region targeted by bN-mAbs. Mann-Whitney U test showed statistically significant 
differences between proviral and plasma viral titers to PG9 (p < 0.0001; Mann-
Whitney U = 0), PG16 (p < 0.005; Mann-Whitney U = 15), PGT128 (p < 0.0001; 
Mann-Whitney U = 5), VRC01 (p < 0.0001; Mann-Whitney U = 0), and 2F5 (p < 
0.0001; Mann-Whitney U = 0). Blue star symbol shows neutralization titers for Env 
EN6_226, used in immunization study. 
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Selection, expression, and bN-mAb binding to recombinant gp120 from the  
EN6_226 clone 
Of the twenty gp120 sequences identified in the elite neutralizer, EN6, one 
(EN6_226) was selected for expression and immunization studies. This sequence was 
selected because it was sensitive to neutralization by autologous plasma, possessed 
only 17 PNGS, lacked the V1 region insertion with extra cysteine residues, and 
possessed epitopes recognized by multiple bN-mAbs. For these studies, codon-
optimized rgp120 gene expressed with a gD-1 purification tag protein was created 
and expressed in HEK293S GnTI- cells. These cells are deficient in N-
acetylglucosaminyltransferase-1 and produce proteins that lack the N-linked sialic 
acid that inhibits the binding of some bN-mAbs (Byrne et al., 2018; Doran et al., 
2018; Morales et al., 2014b; Reeves et al., 2002). The altered glycosylation pathway 
in HEK293S GnTI- cells yields proteins primarily with mannose-5 glycans, which 
have previously been shown to enhance binding of several potent bN-mAbs, 
including PG9 (Doran et al., 2018; Morales et al., 2014b). 
A fluorescent immunoassay (FIA) described previously (Byrne et al., 2018; 
Doran et al., 2018; Hutchinson et al., 2019; Morales et al., 2014b; O’Rourke et al., 
2019) was used to measure EN6_226 rgp120 binding to bN-mAbs. We found that the 
EN6_226 protein bound to PG9, PGT128, and VRC01, but not PG16 and PGT121 
(Fig 2.3). It was surprising that the EN6_226 rgp120 bound to PGT128 since 
EN6_226-recombinant pseudovirus was resistant to neutralization by PGT128. This 
result suggests PGT128 can bind to monomeric gp120 despite E(321+1)R, the 
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putative cause of neutralization resistance to the EN6_226-recombinant pseudovirus. 
While EN6_226 was sensitive to neutralization by PG16, binding to monomeric 
rgp120 was not expected, as the recombinant protein lacked the complex sialic acid 
containing glycans and quaternary structure thought to be required for binding 
(McLellan et al., 2011). PGT121 binding was also not expected, since EN6_226 was 
resistant to neutralization by PGT121. 
 
 
Fig 2.3. Expression and binding of broadly neutralizing monoclonal antibodies 
to EN6_226 rgp120. 
Recombinant EN6_226 gp120 was produced by transient transfection of HEK293S 
GnTI- cells and used for antibody binding assays. Recombinant gp120 from the A244 
isolate of gp120 was used as a positive control. (A) 12µl of supernatant from 
HEK293S GnTI- cells transfected with EN6_226 rgp120, A244 rgp120 (positive 
control), or “mock” (negative control; no env) were analyzed by SDS-PAGE (4-12% 
gel) with and without DTT reduction, blotted, and probed with a mAb (34.1) targeting 
the N-terminal epitope tag. HEK293S GnTI- expressed protein were enriched for 
mannose-5 glycans and thus smaller than sialic acid-enriched proteins produced in 
other cell lines. EN6_226 rgp120 is smaller than A244 rgp120 due to less 
glycosylation and shorter amino acid length. (B) Purified EN6_226 rpg120 was 
captured with 34.1 mAb (34.1) targeting the N-terminal tag and probed with bN-
mAbs PG9, PG16, PGT121, PGT128, and VRC01 by FIA. Purified rabbit polyclonal 
antibodies raised against MN and A244 rgp120s from a previous immunization study, 
PB94, were included as a positive control. Blank (no antigen) was used as a negative 
control. 
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EN6_226 rgp120 elicits stronger neutralization response in rabbits compared to  
two other clade B rgp120s 
Five rabbits were immunized with EN6_226 rgp120. Post-immunization rabbit sera 
were compared to rabbit sera from similar immunization studies using EN3_071 
rgp120 and MN rgp120. EN3_071 rgp120 was derived from a previously described 
elite controller with bNAb activity and normal glycosylation (Hutchinson et al., 
2019). MN rgp120 was used in the RV144 clinical trials, which elicited protective 
non-neutralizing antibody responses, and serves as a clade B immunogen to improve 
upon (Berman et al., 1999, 1996; Doran et al., 2018). All three immunizations elicited 
rgp120-specific antibody binding with comparable IC50s (S5 Fig). 
EN6_226 rgp120 elicited the production of polyclonal antibodies with the 
strongest neutralization response, capable of neutralizing clade B (MN.3 and 
SF162.LS), clade C (MW965.26), and clade CRF01_AE (TH023.6) pseudoviruses 
(Table 2.5). Compared to the other two immunogens, EN6_226 rgp120-raised 
antibodies neutralized SF162.LS, MW965.26, and TH023.6 at higher titers (Table 
2.5). As expected, MN rgp120-raised antibodies neutralized cognate Env MN.3 with 
the highest titers (Table 2.5). EN3_071 rgp120 did not consistently elicit neutralizing 
antibodies (Table 2.5). The strength of the immune response corresponded to the 
amount of glycan holes on the immunogen, with EN6_226 rgp120 eliciting the 
strongest response. 
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Table 2.5. Neutralization of viruses from clades B, C, and CRF01_AE by rabbit 
antibodies raised against EN6_226, EN3_071, and MN rgp120s. 
Rabbits were immunized with EN6_226, EN3_071, or MN rgp120s. Sera were tested 
against a panel of nine Env-recombinant pseudoviruses in a standard neutralization 
assay using TZM-bl cells. Neutralization antibody titers (ID50s) were calculated as 
the reciprocal dilution conferring 50% inhibition. Reactions with neutralization 
activity are shown in grey. Arithmetic mean of titers was calculated with ID50s below 
detection level as zero. CH01-03 and SVA-MLV were included as positive and 
negative controls, respectively. 
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Pepscanning of antisera to EN6_226 rgp120  
Epitope mapping of polyclonal antibodies raised against EN6_226 or MN rpg120 was 
performed by peptide microarray. Because bNAbs bind to conformation and 
glycosylation-dependent epitopes, these studies do not provide information on 
epitopes recognized by neutralizing antibodies. However, they define the spectrum of 
linear epitopes recognized by non-neutralizing antibodies and how they differ when 
elicited by different immunogens. Antibody binding was measured in a peptide 
microarray assay (Gottardo et al., 2013; Zolla-Pazner et al., 2013) in the laboratory of 
Dr. Georgia Tomaras (Duke Medical School, Durham, NC). This assay measured 
antibody binding to 2,058 peptides from eight consensus sequences and five strains 
representing worldwide gp120 sequences. These studies were undertaken with three 
objectives in mind. First, we wanted to define the strongest epitopes and see if they 
differed between EN6_226 rgp120 from a rare elite controller that possessed broadly 
neutralizing antibodies and MN rgp120, a prototypic lab adapted isolate from a 
normal progressor. Second, we were also interested in comparing the immunogenicity 
of EN6_226 rgp120 that possessed only 17 N-linked glycosylation sites compared to 
MN rgp120 that possessed 20 N-linked glycosylation sites. Third, we wanted to see 
the extent to which antibodies were directed to linear peptides in the vicinity of sites 
of vulnerability defined by neutralizing antibodies to the V1/V2 domain (e.g. PG9), 
the V3 domain (e.g. PGT128) and the CD4-binding site (e.g. VRC01). In particular, 
we were interested in whether non-glycosylated peptides from locations that were 
targeted by glycan-dependent broadly neutralizing antibodies were immunodominant 
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or immunorecessive. The gross summary of the results of these studies are shown in 
Figure 2.4. We found that both immunogens elicited antibodies with the strongest 
binding to multiple linear epitopes in the C1, C2, C4, and V5 regions (Fig 2.4A). Of 
these, both the C4 domain and the V5 domain are known to possess residues 
recognized by monoclonal antibodies that block CD4 binding. The EN6_226 rgp120-
raised antibodies showed significantly stronger binding to peptides in the V3 region 
compared to those raised against MN rgp120 (Fig 2.4A). The V3 domain is known to 
possess contact residues recognized by multiple neutralizing antibodies. The 
enhanced binding to the V3 region may be due to a reduction in glycan shielding 
attributable to the absence of glycosylation sites at residues 295 and 402 in EN6_226 
rgp120, which are present in MN rgp120 (Fig 2.4B). 
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Fig 2.4. Pepscanning to compare linear epitopes targeted by rabbit antibodies 
raised against EN6_226 or MN rgp120s. 
Pepscanning of polyclonal antibodies raised against rgp120 immunogens was 
performed by peptide microarray as described previously (Shen et al., 2015). (A) 
Heatmap shows median magnitude of peptide binding (signal) for rabbit antibodies 
raised against EN6_226 or MN rgp120s. Peptide library was composed of 15-mers 
that overlapped by 12 amino acids for thirteen different gp120 sequences, shown by 
row. Schematic above the heatmap shows peptide locations in gp120, aligned for each 
column. (B) Homology models of rgp120 immunogens were built using Modeller 
v9.21 (Webb and Sali, 2016) with PDB ID 5aco template (Pancera et al., 2014) and 
N-linked glycans were added with GLYCAM Web Glycoprotein Builder (Woods 
Group, 2005). Amino acid rgp120 residues are shown in blue; N-linked glycans are 
shown in light grey. 
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Next, we ranked peptides with the highest antibody binding signals to 
determine immunodominant regions. EN6_226 rgp120-raised antibodies showed the 
strongest binding to clade B peptides in non-neutralizing regions (C1, C2, and C5) 
but the fifth highest response was to a V5 peptide located in the CD4-binding site and 
the seventh and ninth highest responses were to V3 peptides in the PGT128 epitope 
(Table 2.6A). MN rgp120-raised antibodies showed the strongest binding to clade B 
peptides from the CD4-binding site (Table 2.6B). Similar results were observed for 
antibody binding to peptides from all clades (Table 2.7). 
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Strongest antibody binding signals to clade B peptides 
A 
gp120 
region Clade B peptides HXB2 range 
anti-EN6 sera 
(median signal) 
C1 NNMVEQMHEDIISLW 98 - 112 9.66 
C2 PVVSTQLLLNGSLAE 253 - 267 9.38 
C1 MHEDIISLWDQSLKP 104 - 118 9.12 
C5 SELYKYKVVKIEPLG 481 - 495 8.83 
V5* NTTETFRPGGGDMRD 463 - 477 8.65 
C1 TDPNPQEVVLENVTE 77 - 91 8.43 
V3** YATGDIIGDIRQAHC 318 - 332 8.34 
C1 VEQMHEDIISLWDQS 101 - 115 8.28 
V3** RAFYATGDIIGDIRQ 315 - 329 8.24 
V5 NNNNTTETFRPGGGD 92 - 106 8.01 
 
B 
gp120 
region Clade B peptides 
HXB2 
range 
anti-MN sera 
(median signal) 
C5* MRDNWRSELYKYKVV 475 - 489 9.74 
C4* QIRCSSNITGLLLTR 442 - 456 9.35 
C5* GGDMRDNWRSELYKY 472 - 486 9.06 
C4* CSSNITGLLLTRDGG 445 - 459 8.97 
C5* ETFRPGGGDMRDNWR 466 - 480 8.75 
C2 PVVSTQLLLNGSLAE 253 - 267 8.22 
C1 NNMVEQMHEDIISLW 98 - 112 8.05 
C5* NWRSELYKYKVVKIE 478 - 492 7.99 
C1 MHEDIISLWDQSLKP 104 - 118 7.96 
C2 STQLLLNGSLAEEEV 256 - 270 7.80 
*CD4-binding site (VRC01 contacts) 
**V3 region (PGT128 contacts) 
 
Table 2.6. Strongest antibody binding signals to clade B peptides. 
Pepscanning of polyclonal antibodies raised against rgp120 immunogens was 
performed by peptide microarray. Peptide locations were compared to previously 
published data to identify sites of interest, including functional regions and bN-mAb 
epitopes. Peptides from sites of interest are shown in bold. (A) Highest median clade 
B peptide binding signals for rabbit antibodies raised against EN6_226 rgp120. (B) 
Highest median clade B peptide binding signals for rabbit antibodies raised against 
MN rgp120. 
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Strongest cross-reactive antibody binding signals to peptides from all major clades 
A 
gp120 
region All peptides 
HXB2 
range 
anti-EN6 sera 
(median signal) 
C1 NNMVEQMHTDIISLW 98 - 112 9.69 
C1 VEQMHEDIISLWDES 101 - 115 9.68 
C1 NNMVEQMHEDIISLW 98 - 112 9.66 
C5 SELYKYKVVRIEPLG 481 - 495 9.61 
V3** QALYTTRIIGDIRQ 315 - 329 9.51 
V5* TNNETFRPGGGNIKD 463 - 477 9.44 
C5 NELYKYKVVQIEPLG 481 - 495 9.43 
C2 PVVSTQLLLNGSLAE 253 - 267 9.38 
V5* TNNTNNETFRPGGGN 460 - 474 9.31 
C1 NDMVEQMHEDIISLW 98 - 112 9.27 
 
B 
gp120 
region All peptides 
HXB2 
range 
anti-MN sera 
(median signal) 
C5* MRDNWRSELYKYKVV 475 - 489 9.74 
C4* LIRCSSNITGLLLTR 442 - 456 9.68 
C5* MKDNWRSELYKYKVV 475 - 489 9.67 
C4* NITGILLTRDGGATN 448 - 462 9.66 
C4* EIRCESNITGLLLTR 442 - 456 9.49 
C5* IKDNWRSELYKYKVV 475 - 489 9.40 
C4* QIRCSSNITGLLLTR 442 - 456 9.35 
C4* NITCKSNITGLLLTR 442 - 456 9.34 
C5* GGDMRDNWRSELYKY 472 - 486 9.06 
C4* CSSNITGLLLTRDGG 445 - 459 8.97 
*CD4-binding site (VRC01 contacts) 
**V3 region (PGT128 contacts) 
 
Table 2.7. Strongest cross-reactive antibody binding signals to peptides from all 
major clades. 
Pepscanning of polyclonal antibodies raised against rgp120 immunogens was 
performed by peptide microarray. Peptide locations were compared to previously 
published data to identify sites of interest, including functional regions and bN-mAb 
epitopes. Peptides from sites of interest are shown in bold. (A) Highest median 
peptide binding signals for rabbit antibodies raised against EN6_226 rgp120. (B) 
Highest median peptide binding signals for rabbit antibodies raised against MN 
rgp120.  
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 Since previous studies have shown that neutralizing antibodies are directed to 
glycan holes, we analyzed antibody binding signals to non-glycosylated peptides with 
sequences encoding potential N-linked glycosylation sites. Overall, locations lacking 
PNGS did not consistently show higher antibody responses when compared to the 
other immunogen containing a PNGS at the same location, suggesting that these 
regions are inherently immunorecessive (Table 2.8).  
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Antibody binding to peptides at PNGS locations 
 PNGS Clade B peptides All peptides 
HXB2 # EN6_226 MN EN6 MN EN6 MN 
88   N 1.06 1.22 0.06 1.37 
130   N 3.43 5.84 0.54 5.75 
136   N 0.00 0.00 0.00 0.00 
142   N 0.00 0.14 0.00 0.00 
142+5   N 6.80 0.00 0.00 0.00 
156 N N 2.00 0.00 0.00 0.00 
160 N N 0.00 0.00 0.00 0.00 
186 N N 0.00 4.08 0.00 0.00 
197 N N 0.00 0.00 0.00 0.00 
241 N N 0.00 0.49 0.00 0.00 
262 N N 2.73 3.86 0.58 1.69 
276 N   0.00 1.00 0.00 4.25 
289 N   2.32 0.85 0.00 0.00 
295   N 0.00 0.00 0.00 0.00 
301 N   0.00 0.00 0.00 0.00 
332 N   0.00 0.00 0.00 0.00 
339   N 0.00 0.00 0.00 0.00 
356 N N 0.00 0.35 0.00 0.00 
386 N N 0.00 0.00 0.00 0.00 
397 N N 0.00 0.07 0.00 0.00 
405 N  0.00 0.00 0.00 0.00 
406   N 0.00 0.00 0.00 0.00 
409 N   0.00 0.00 0.00 0.00 
413   N 0.00 0.00 0.00 0.00 
448 N N 2.19 9.35 1.10 8.24 
463 N N 7.64 6.17 7.72 5.92 
 
Table 2.8. Antibody binding to peptides at PNGS locations. 
Pepscanning of polyclonal antibodies raised against rgp120 immunogens was 
performed by peptide microarray. EN6_226 rgp120 and MN rgp120 sequences were 
aligned to HXB2 reference with MUSCLE (Edgar, 2004). All EN6_226 and MN 
rgp120 PNGS locations are listed in columns 2 and 3. Median antibody binding 
signals are shown for peptides containing residues at PNGS locations.  
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Next, we compared antibody binding signals to determine which immunogen 
elicited stronger responses to sites of interest, including the V2 peptide that correlated 
with protection in the RV144 study. MN rgp120-raised antibodies showed stronger 
binding to V2 peptides from each clade and the aggregated of all clades, with the 
exception of clade A (Table 2.9). EN6_226 rgp120-raised antibodies elicited a 
stronger response to the clade A V2 peptide (Table 2.9), which was the only sequence 
in this region that did not correlate with protection (Gottardo et al., 2013). 
 
Antibody binding to V2 peptides (RV144 correlate of protection) 
Source Sequence anti-EN6 sera (binding signal) 
anti-MN sera 
(binding signal) 
A.con TELRDKKQKVYSLFY 1.23 0.82 
A244/TH023 TELRDKKQKVHALFY 0.00 0.00 
CRF01.AE/CRF02_AG TELRDKKQKVYALFY 0.79 0.88 
B.con TSIRDKVQKEYALFY 1.37 3.98 
M.con/C.con TEIRDKKQKVYALFY 0.98 0.99 
D.con TEVRDKKKQVYALFY 0.48 0.65 
Aggregate N/A 0.79 0.88 
 
Table 2.9. Antibody binding to V2 peptides (RV144 correlate of protection). 
Pepscanning of polyclonal antibodies raised against rgp120 immunogens was 
performed by peptide microarray. Median binding signals are shown for antibodies 
raised against EN6_226 or MN rgp120s to V2 peptides from each major clade and an 
aggregate of all clades tested. 
 
 
To determine which immunogen elicited a stronger response to sites of 
vulnerability, we compared antibody binding to peptides from the PG9, PGT128, and 
VRC01 epitopes, which target the V1/V2 region, V3 region, and CD4-binding site, 
respectively. EN6_226 rgp120-raised antibodies had higher binding signals to clade B 
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peptides from the V3-targeting PGT128 epitope. Conversely, MN rgp120-raised 
antibodies showed stronger binding to clade B peptides in the V2-targeting PG9 
epitope and CD4-binding site. Binding signal from an aggregate of all clades showed 
the same results. 
 
A 
Antibody binding to sites of vulnerability 
(peptides from clade B consensus sequence) 
Site of 
vulnerability Peptide HXB2 range 
anti-EN6 sera 
(binding signal) 
anti-MN sera 
(binding signal) 
V2 region 
(PG9 contacts) 
IKNCSFNITTSIRDK 154 - 168 0.00 0.00 
CSFNITTSIRDKVQK 157 - 171 0.00 0.11 
NITTSIRDKVQKEYA 160 - 174 0.00 2.75 
V3 region 
(PGT128 contacts) 
RPNNNTRKSIHIGPG 298 - 312 5.36 0.00 
NNTRKSIHIGPGRAF 301 - 315 5.50 5.61 
RKSIHIGPGRAFYAT 304 - 318 7.00 6.11 
IHIGPGRAFYATGDI 307 - 321 2.50 1.23 
GPGRAFYATGDIIGD 312 - 326 0.00 0.35 
RAFYATGDIIGDIRQ 315 - 329 8.24 0.92 
YATGDIIGDIRQAHC 318 - 332 8.34 0.00 
GDIIGDIRQAHCNIS 321 - 335 6.95 0.00 
CD4-binding site 
(VRC01 contacts) 
SENFTDNAKTIIVQL 274 - 288 0.00 0.00 
FNQSSGGDPEIVMHS 361 - 375 1.28 3.15 
SSGGDPEIVMHSFNC 364 - 378 0.51 1.74 
KQIINMWQEVGKAMY 421 - 435 0.00 0.46 
GLLLTRDGGNNNNTT 451 - 465 0.00 3.44 
ETFRPGGGDMRDNWR 466 - 480 6.63 8.75 
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B 
Cross-reactivity to sites of vulnerability 
(aggregate antibody binding signal from 12 sequences) 
Site of vulnerability HXB2 range anti-EN6 sera (binding signal) 
anti-MN sera 
(binding signal) 
V2 region 
(PG9 contact sites) 
154 - 168 0.00 0.00 
157 - 171 0.00 0.00 
160 - 174 0.00 0.00 
V3 region 
(PGT128 contact sites) 
298 - 312 5.36 0.62 
301 - 315 3.68 0.00 
304 - 318 4.80 2.33 
307 - 321 0.00 0.00 
312 - 326 0.00 0.00 
315 - 329 5.70 0.00 
318 - 332 7.07 0.00 
321 - 335 6.61 0.00 
CD4-binding site 
(VRC01 contact sites) 
274 - 288 0.23 0.00 
361 - 375 0.00 5.20 
364 - 378 0.00 1.33 
421 - 435 0.00 0.00 
451 - 465 0.00 3.31 
466 - 480 7.51 8.49 
 
Table 2.10. Antibody binding to sites of vulnerability. 
Pepscanning of polyclonal antibodies raised against rgp120 immunogens was 
performed by peptide microarray. Binding signals are shown for antibodies raised 
against EN6_226 or MN rgp120s. (A) Median antibody binding signals to clade B 
peptides from PG9, PGT128, and VRC01 contact sites. (B) Median antibody binding 
signals to all peptides from PG9, PGT128, and VRC01 contact sites. 
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Discussion 
In these studies, we consider the possibility that Envs from rare individuals who 
produced potent bNAbs and controlled their infection without ART (EN/controller 
phenotype) might possess unusual features that contributed to the formation of 
effective antiviral immune responses. To identify EN/controllers for this study, we 
first screened a cohort of ART-naïve controllers for neutralization breadth. Consistent 
with previous studies, elite controllers as a group exhibited lower neutralization 
potency and breadth compared to viremic controllers in the cohort (Bailey et al., 
2006; Doria-Rose et al., 2010, p., 2009; González et al., 2018; Lambotte et al., 2009; 
Pereyra et al., 2008). Because elite controllers, by definition, possess low or 
undetectable viral loads (<50 HIV RNA copies/ml)(Okulicz et al., 2009), the amount 
of circulating immunogen is usually insufficient to drive the antibody affinity 
maturation process that appears necessary to develop bNAbs (Corti et al., 2010; 
Scheid et al., 2009; Walker et al., 2009, p. 2; Wu et al., 2010; Xiao et al., 2009a, 
2009b). In contrast, viremic controllers (100 – 1,000 HIV RNA copies/ml) have viral 
loads that dip and rise, providing antigenic stimulation that leads to neutralization 
breadth at similar rates to non-controllers (Bailey et al., 2006; Doria-Rose et al., 
2010). From the EN/controllers identified, we further characterized EN6, who 
exhibited elite neutralizing activity (found in <1% of HIV-positive individuals 
(Simek et al., 2009)) and maintained viremic control for over 17.5 years without 
antiretroviral therapy (found in <2% of HIV-positive individuals (Okulicz et al., 
2009)). 
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Our study enabled us to identify two major structural features that may have 
enhanced the protective immune response in EN6. The first was a highly unusual and 
statistically significant decrease in the number of PNGS (17) compared to the normal 
number of PNGS (26) found in most gp120s. A reduction in the number of N-linked 
glycosylation sites would be expected to expand glycan holes, exposing regions of 
protein surface that are normally shielded from the immune system by glycans, and 
increase immunogenicity (Zhou et al., 2017). Notably, the Env retained PNGS at 
conserved sites targeted by several prototypic bN-mAbs, including N156, N160, 
N301, and N332 (Julien et al., 2013b, p. 121; Kong et al., 2015, p. 16; McLellan et 
al., 2011, p. 9; Pejchal et al., 2011). The region of Env with the greatest reduction of 
PNGS was V1, which has been called the “global regulator” of neutralization (Pinter 
et al., 2004). The V1/V2 domain is known to be the initial target for autologous 
neutralizing antibodies as well as bN-mAbs, such as PG9 and PG16 (McLellan et al., 
2011). Additionally, changes in the V1/V2 domain affect CD4 binding to monoclonal 
antibodies that facilitate ADCC, such as A32 (Prévost et al., 2018). 
The second unusual structural feature we observed in this individual was the 
presence of two non-conserved cysteine residues in an elongated V1 region, which is 
found in only 5.5% of clade B Env sequences (van den Kerkhof et al., 2016). While 
the vast majority of HIV Env proteins possess 18 cysteines that form 9 disulfide 
bridges, the proviral sequences from EN6 possessed 20 cysteines. The two additional 
cysteines can potentially form a disulfide loop in a conventional thumb and mitt 
structure or contribute to a wide variety of alternative disulfide bonds by pairing with 
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other cysteine residues that contribute to the normal disulfide structure described by 
Leonard et al (Leonard et al., 1990). In previous studies, we identified Env proteins 
with 20 Cys in subjects that participated in the VAX004 clinical trials (Jobes et al., 
2006). The extra Cys residues frequently occurred as an insertion in the V1 region 
between positions 131 and 144 (Jobes et al., 2006). Aberrant cysteines in the V1 
region were recently found in two elite neutralizers (S6 Table)(van den Kerkhof et al., 
2016) and an elite controller (Silver et al., 2019). Significantly, we also identified 
Envs possessing 20 Cys in another elite controller with broadly neutralizing activity 
(EN3) from the SCOPE cohort (Hutchinson et al., 2019). In these studies, there is 
some evidence that epistatic mutations are required to accommodate the unusual 
cysteines in order to preserve infectivity, suggesting a functional role (Hutchinson et 
al., 2019; Silver et al., 2019; van den Kerkhof et al., 2016). However, it remains 
unclear if cysteines are introduced stochastically, possibly from a duplication event as 
described in van den Kerkhoff et al, 2016, or if they are a result of selection pressure. 
The effect of non-canonical cysteines in V1, separate from length and glycosylation, 
warrants further study. 
Two distinct Env variants were identified in EN6, proviral Envs with long, 
heavily glycosylated V1 regions with additional cysteines and plasma Envs with 
minimal glycosylation and short V1 regions. These two variants may reflect dual 
pressure to mediate immune escape and transmission fitness, respectively. The long, 
heavily glycosylated V1 regions in proviral Envs is a mechanism for early viral 
escape from strain-specific neutralizing antibodies and several known bN-mAbs 
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(Bunnik et al., 2008; Krachmarov et al., 2005, 2006; Liu et al., 2011; Mikell et al., 
2011; O’Rourke et al., 2015; Richman et al., 2003; Rong et al., 2007; Sagar et al., 
2006; van den Kerkhof et al., 2016; van Gils et al., 2011). In contrast, the plasma 
Envs share similar features to the transmitter/founder phenotype, where the short, 
unglycosylated V1 region may improve infectivity at the expense of exposing 
neutralizing epitopes (Chohan et al., 2005; Dacheux et al., 2004; Derdeyn et al., 2004; 
Wu et al., 2006). Indeed, plasma-derived Envs were sensitive to neutralization by V2-
glycan targeting bN-mAbs (PG9 and PG16) and CD4-binding site-targeting bN-mAb 
(VRC01) while the proviral-derived Envs were resistant. 
The primary goal of this study was to identify an Env that may elicit the 
production of bNAbs. Since bNAbs usually do not appear until two years post 
infection (Sather et al., 2009) and with virus rapidly escaping the antibody response, 
contemporaneous Envs are unlikely to have stimulated the production of bNAbs. One 
approach to identify the species likely to have elicited bNAbs is to carry out long 
term longitudinal studies (Doria-Rose et al., 2014; Gray et al., 2011; Landais et al., 
2016) or evolutionary reconstructions (Mesa et al., 2019) to identify species that 
occurred immediately prior to the appearance of bNAbs. Here we describe another 
approach to this problem where we take advantage of sequences from rare individuals 
able to control virus replication and may exhibit lower Env diversity. Analysis of the 
first individual that we studied with the unusual EN/controller phenotype showed a 
low level of Env sequence variation (98.5% sequence identity) and a low number of 
PNGS in gp120 (17 PNGS) from the plasma virus. When expressed, we found that 
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Envs were infectious and elicited antibody responses that appeared to be superior to 
antibody responses elicited by two other clade B Envs, including MN rgp120 used in 
previous vaccine studies. Taken together, our results suggest that further studies of 
the Envs from individuals with the dual EN/controller phenotype are warranted. The 
immunological potential of the Envs we identified here will require comparing the 
immunogenicity of alternate immunogen structures, such as trimeric gp140s (Sanders 
et al., 2015), and alternate immunization strategies, such as prime boosting with virus 
vectors (Hansen et al., 2013) or guided immunization (Haynes et al., 2012). 
 
Materials and methods 
Clinical samples 
Plasma and non-viable peripheral blood mononuclear cell (PBMC) samples were 
provided by the Women’s Interagency HIV Study (WIHS, Baltimore, MD) after 
review and approval of this study. The WIHS is a multicentered longitudinal study of 
HIV-infected women in the United States (Bacon et al., 2005; Barkan, 1998). All 
WIHS participants provided written informed consent, including permission to store 
and use specimens for research. The University of California, San Francisco 
Institutional Review Board approved consent forms and protocols for the Northern 
California location. The initial recruitment interview included self-identification of 
race and sex. After enrollment, participants visited a research site every six months 
for an interview, clinical examination, and blood draws. Blood specimens from each 
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visit were used for laboratory testing, which included viral load and CD4+ cell count, 
and stored in the WIHS repository. 
A subset of 53 HIV-positive ART-naïve African American women was 
selected based on their ability to control viral load and CD4+ cell count for prolonged 
periods without ART. Individuals were categorized into four groups, elite controllers 
(<100 HIV RNA copies/ml for three consecutive visits over >12 months), viremic 
controllers (100 – 1,000 HIV RNA copies/ml for three consecutive visits over >12 
months), long-term nonprogressors (no periods of elite or viremic control and >500 
CD4+ cells/µl for at least 7 years), and normal progressors (no periods of elite or 
viremic control nor 7+ year period with >500 CD4+ cells/µl). From each individual, 
de-identified cryopreserved plasma samples from two visits were selected and 
assayed for neutralization potency and breadth against Env-recombinant viruses. Five 
individuals capable of neutralizing pseudoviruses from at least 4/5 clades were 
selected and specimens (plasma and PBMCs) from the earlier of the two visits were 
used for subsequent analyses. 
 
Neutralization assays 
Initial virus neutralization assays were performed at Monogram Biosciences (South 
San Francisco, CA) with a previously described panel of five viruses useful for 
detecting elite neutralizers (Simek panel)(Frost et al., 2005; Richman et al., 2003; 
Simek et al., 2009). This assay utilized Env-recombinant pseudoviruses generated 
from patient samples or a panel of well-characterized viruses. A second panel of 
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twenty-two pseudoviruses representing all major subtypes of HIV-1 (clades A, B, C, 
D, and AE) was used to characterize the antibodies in plasma from individuals 
possessing bNAbs as indicated by the Simek panel. A panel of broadly neutralizing 
monoclonal antibodies (bN-mAbs) was also assembled that contained bN-mAbs PG9, 
PG16, PGT121, PGT128, and VRC01 that were provided by the NIH AIDS Reagent 
Program, the NIH Vaccine Research Center Polymun Scientific (Vienna, Austria), or 
synthesized in our lab based on published sequences. Neutralization antibody titers 
were calculated as the reciprocal plasma dilution (ID50) or reciprocal mAb 
concentration (IC50) conferring 50% inhibition, as measured by luciferase activity. 
Positive neutralization calls required an ID50 or IC50 that is at least three-fold greater 
than the specificity control, a pseudovirus made with the amphotropic murine 
leukemia virus (aMLV) envelope protein. Pseudoviruses with clade B NL4-3 and 
JRCSF rgp160s were included as CXCR4- and CCR5-dependent positive controls, 
respectively. Broadly neutralizing plasma (Z23) was included in all assays as an 
additional positive control. This assay has been validated and widely used in HIV 
research (Simek et al., 2009; Walker et al., 2011, 2009). 
 Rabbit sera to recombinant Env proteins was tested with a standard TZM-bl 
neutralization protocol and performed on two separate days at Duke University 
(Durham, NC). Positive neutralization calls required 50% inhibition. SVA-MLV was 
used as a specificity control and CH01-31 was used as a positive control. This assay 
has been optimized and validated for accurate result, as previously described 
(Montefiori, 2005; Sarzotti-Kelsoe et al., 2014). 
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Sequencing and coreceptor usage 
Sequencing and coreceptor usage assays were performed at Monogram Biosciences 
(South San Francisco, CA) with a previously described protocol (Whitcomb et al., 
2007). Briefly, env libraries generated from patient plasma or PBMCs were used to 
make pseudoviruses. Pseudoviruses were then grown and screened for infectivity. 
Full-length envs from 10 plasma-derived and 10 PBMC-derived infectious 
pseudoviruses were sequenced. Chemokine receptor usage of the 20 sequenced 
pseudoviruses was determined by inoculating U87 expressing CD4+ and either 
CCR5+ or CXCR4+ and measuring luciferase activity. This coreceptor usage assay 
has been validated in accordance with Clinical Laboratory Improvement 
Amendments (CLIA) regulations. 
 
Datasets and statistical analysis 
Patient-derived gp160s were compared to the Los Alamos National Laboratory HIV 
Sequence Database Filtered web alignment for clade B Env proteins curated in 2017 
(“HIV sequence database main page,” n.d.). Statistical analyses were performed in 
GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA) using the nonparametric 
Kruskal-Wallis and Mann-Whitney U tests. 
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Expression and purification of recombinant gp120 
Codon-optimized gp120 fusion genes were designed with an N-terminal purification 
tag gD-1, herpes simplex virus 1 glycoprotein D (O’Rourke et al., 2019). Genes were 
synthesized (Invitrogen, Inc., Carlsbad, CA) and inserted into a pCF vector with a 
cytomegalovirus promoter using Gibson Assembly® (New England Biolabs, Inc., 
Ipswich, MA). Recombinant plasmids were verified with Sanger sequencing (UC 
Berkeley, Berkeley, CA), transformed into 5-alpha Competent E. coli cells (New 
England Biolabs, Inc., Ipswich, MA), then purified (QIAGEN, Hilden, Germany). 
HEK293S GnTI- cells (ATCC® CRL-3022™), that lack N-
acetylglucosaminyltransferase-1 (Reeves et al., 2002), were transfected using 
Maxcyte electroporation system HEK293 protocol (MaxCyte STX®, MaxCyte, Inc., 
Gaithersburg, MD). The cells were grown in shake flask cultures (FreeStyle™ 293 
Expression Medium, Invitrogen Inc., Waltham, MA) and harvested five days after 
transfection. Secreted gp120 was purified by immunoaffinity chromatography 
(O’Rourke et al., 2019) followed by size exclusion chromatography (Sephacryl S-
200, GE Healthcare Life Sciences, Marlborough, MA). 
Growth conditioned cell culture supernatants with and without 25mM 
dithiothreitol (DTT) were run on a NuPAGE™ 4-12% Bis-Tris precast gel 
(Invitrogen™, Carlsbad, CA) in MES running buffer (Invitrogen™, Carlsbad, CA). 
Protein was transferred to a polyvinylidene fluoride (PDVF) membrane using 
standard protocol for iBlot (ThermoFisher Scientific, Waltham, MA). Membrane was 
blocked in 5% milk, probed with 0.2 µg/ml mouse anti-gD-1 monoclonal antibody 
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34.1 (lot A16.02, UC Santa Cruz, Santa Cruz, CA)(O’Rourke et al., 2019), then 
1:5,000 dilution of HRP-conjugated anti-mouse secondary antibody (Jackson 
ImmunoResearch, West Grove, PA). Antibody was detected using WesternBright 
reagents (Advansta, Menlo Park, CA) and visualized using Innotech FluoChem2 
system (Genetic Technologies, Grover, MO). 
 
Antibody binding assays 
Antibody binding to rgp120 was assessed using fluorescent immunoassay (FIA). 96 
well black microplates (Greiner Bio-One, Monroe, NC) were coated with 2 µg/ml of 
purified mouse anti-gD-1 mAb 34.1 (lot A69, UC Santa Cruz, Santa Cruz, CA) in 
PBS overnight at 4°C. Plates were blocked with 2.5% BSA in PBS for 4 h on a shaker 
at room temperature. Purified EN6_226 rgp120 at 2 µg/ml in PBST was captured 
overnight on a shaker at room temperature. Primary antibodies were added in 
duplicate serial 1:3 dilutions starting with either undiluted rabbit sera or 10 µg/ml of 
bN-mAbs PG16 (lot 130229, NIH AIDS Reagent Program, Germantown, MD), PG9, 
PGT121, PGT128, VRC01 (lots A62, A9, A32, A27, respectively, UC Santa Cruz, 
Santa Cruz, CA) in PBST and incubated on a shaker at room temperature for 1.5 h. 
Purified rabbit polyclonal antibodies raised against MN and A244 rgp120s from a 
previous immunization study, PB94 (lot A19.3, UC Santa Cruz, Santa Cruz, CA), 
were included as a positive control. Blank (no antigen) or pre-immune rabbit sera 
were used as negative controls. Dilutions of 1:5000 goat anti-human Alexa Flour® 
488-conjugated IgG Fcg polyclonal Ab (lot 137248, Jackson ImmunoResearch 
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Laboratories, Inc, West Grove, PA) or goat anti-rabbit Alexa Flour® 488-conjugated 
IgG (H+L) polyclonal Ab (lot 1981125, Invitrogen, Inc., Carlsbad, CA) were 
incubated on a shaker at room temperature for 1 h. Between each step, plates were 
washed four times in PBST. Plates were visualized using EnVision™ Multilabel Plate 
Reader (PerkinElmer, Inc., Waltham, MA) with FITC 485 excitation and 535 
emission filters. 
 
Rabbit immunization studies 
Rabbit immunization studies were conducted in accordance with the Animal Welfare 
Act at Pocono Rabbit Farm & Laboratory (Canadensis, PA), a facility fully accredited 
by Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC 925) and assured by the National Institute of Health (NIH) 
and Office of Laboratory Animal Welfare (OLAW A3886-01). The Pocono Rabbit 
Farm & Laboratory Institutional Animal Care and Use Committee (IACUC) approved 
the immunization protocol (PRF2A). 
For immunogens rgp120 EN6_226 and EN3_071, five New Zealand White 
rabbits were immunized with 200 µg/dose produced in HEK293S GnTI- cells 
(ATCC® CRL-3022TM), delivered intradermally on days 0, 28, 56, and 140. The 
primary immunization was formulated with Complete Freund’s Adjuvant (CFA) 
while the subsequent three boosts were formulated with Incomplete Freund’s 
Adjuvant (IFA). Bleeds were taken from each rabbit on days 0 (pre-immune), 42, 70, 
and 147. Control rabbit sera to MN rgp120 was produced in two New Zealand White 
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rabbits immunized according to a standard protocol provided by Pocano Labs 
designed to elicit high affinity antibodies (PRF2A). 
 
Peptide microarray 
Peptide microarray was performed at Duke University (Durham, NC). Serial dilutions 
of rabbit sera starting at 1:50 were tested against 15-mer peptides overlapping by 12 
and covering consensus gp160s for clade A, B, C, D, group M, CRF1, and CRF2 and 
vaccine gp120s 1.A244, 1.TH023, MN, C.1086, C.TV1, and C.ZM651 (library 2738, 
JPT Peptide Technologies, Berlin, Germany). Binding was detected with 1:500 
dilution of goat anti-rabbit IgG Alexa Fluor® 647 polyclonal Ab and visualized with 
InnoScan function XDR (Stevanato Group, Padua, Italy). Microarray data was 
processed using R package pepStat (Imholte et al, 2013) to determine intensity for 
each peptide. For EN6_226, the magnitude of binding (signal) was measured as log2 
(intensity of the post-immunization sample / intensity of the pre-immunization 
sample). For MN, the magnitude of binding was measured as log2 (intensity of the 
post-immunization sample / 50th percentile value). 
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2.S1 Table. Neutralization potency and breadth in 28 elite controllers. 
Cryopreserved, de-identified plasma from 28 elite controllers were obtained and 
tested for the presence of virus neutralizing antibodies using a panel of pseudotype 
viruses. Elite controllers are defined as HIV-positive individuals with <100 HIV 
RNA copies/ml for three consecutive visits over >12 months. For each individual, 
samples from two time points were assayed against pseudoviruses from a standard 
panel of five Envs representing global strains. Assays included positive control Z23, 
plasma containing broadly neutralizing antibodies, and average titers are shown in the 
table. ID50 titers are defined as the reciprocal of the plasma dilution that inhibits 50% 
luciferase activity in U87 cells. Bold values indicate ID50s at least three times greater 
than the negative control (aMLV). 
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2.S2 Table. Neutralization potency and breadth in 15 viremic controllers. 
Cryopreserved, de-identified plasma from 15 viremic controllers were obtained and 
tested for the presence of virus neutralizing antibodies using a panel of pseudotype 
viruses. Viremic controllers are defined as HIV-positive individuals with 100 - 1,000 
HIV RNA copies/ml for three consecutive visits over >12 months. For each 
individual, samples from two time points were assayed against pseudoviruses from a 
standard panel of five Envs representing global strains. Assays included positive 
control Z23, plasma containing broadly neutralizing antibodies, and average titers are 
shown in the table. ID50 titers are defined as the reciprocal of the plasma dilution that 
inhibits 50% luciferase activity in U87 cells. Bold values indicate ID50s at least three 
times greater than the negative control (aMLV). 
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2.S3 Table. Neutralization potency and breadth in 4 long-term nonprogressors.  
Cryopreserved, de-identified plasma from 4 long-term nonprogressors were obtained 
and tested for the presence of virus neutralizing antibodies using a panel of 
pseudotype viruses. Long-term nonprogressors are defined as HIV-positive 
individuals with no periods of elite or viremic control and > 500 CD4+ cells/µl for at 
least 7 years. For each individual, samples from two time points were assayed against 
pseudoviruses from a standard panel of five Envs representing global strains. Assays 
included positive control Z23, plasma containing broadly neutralizing antibodies, and 
average titers are shown in the table. ID50 titers are defined as the reciprocal of the 
plasma dilution that inhibits 50% luciferase activity in U87 cells. Bold values indicate 
ID50s at least three times greater than the negative control (aMLV). 
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2.S4 Table. Neutralization potency and breadth in 6 normal progressors. 
Cryopreserved, de-identified plasma from 5 normal progressors were obtained and 
tested for the presence of virus neutralizing antibodies using a panel of pseudotype 
viruses. Normal progressors are defined as HIV-positive individuals with no periods 
of elite or viremic control nor a 7+ year period with > 500 CD4+ cells/µl. For each 
individual, samples from two time points were assayed against pseudoviruses from a 
standard panel of five Envs representing global strains. Assays included positive 
control Z23, plasma containing broadly neutralizing antibodies, and average titers are 
shown in the table. ID50 titers are defined as the reciprocal of the plasma dilution that 
inhibits 50% luciferase activity in U87 cells. Bold values indicate ID50s at least three 
times greater than the negative control (aMLV). 
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2.S5 Fig. Comparison of rabbit antibody titers elicited by rgp120s from 
controllers (EN6_226 and EN3_071) and MN rgp120. 
Recombinant gp120s (EN6_226 and EN3_071) expressed in HEK293 GnTI- cells 
were purified and used to immunize rabbits. The resulting sera were tested for 
antibody binding to antisera prepared against MN rgp120. Purified EN6_226 rgp120s 
fusion protein was captured with mouse anti-gD-1 mAb (targeted the N-terminal tag). 
Purified rabbit polyclonal antibodies raised against MN and A244 rgp120s from a 
previous immunization study, PB94, were included as a positive control. Pre-immune 
blood sera and no primary antibody served as a negative control. Antibodies raised 
against EN6_226, EN3_071, MN rgp120 or positive control showed similar binding 
to purified EN6_226 rgp120 (IC50s = 3.1µl/ml, 1.3µl/ml, 2.0µl/ml, and 3.0µl/ml, 
respectively). 
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2.S6 Table. Physical characteristics of functional proviral and plasma gp160 
sequences isolated from EN7. 
The number of amino acids, potential N-glycosylation sites (PNGS), and cysteines 
were counted in each region of functional gp160 sequences isolated from EN7 PBMC 
and plasma samples. Location of PNGS was defined as the location of N in NX(S/T) 
motif (where X is any amino acid except proline). The distribution of each measure 
was compared to clade B sequences from the Los Alamos National Laboratory 2017 
Filtered Web Alignment. EN7 functional proviral sequences had an elongated V1 
region with two unusual cysteines. 
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Chapter 3:  Targeted amplicon sequencing – application of Tn5-enabled and 
molecular identifier-guided amplicon assembly (TMIseq) to env V1 – V3 region 
and immunoglobulin heavy chain (IGH) VDJ region. 
 
Adapted from National Institutes of Health grant R01AI113893 report and poster 
presented at National Human Genome Research Institute Meeting, 13 April 2017. 
The content is solely the responsibility of the authors and does not necessarily 
represent the official views of the National Institutes of Health. 
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Cole and Roger Volden. Samples were provided by Phillip W. Berman. Sara M. 
O’Rourke assisted with processing samples. Data analysis performed and summarized 
by Jennie M. Hutchinson.  
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Introduction 
A new targeted amplicon sequencing method (TMIseq) has been developed that 
overcomes major obstacles for sequencing critical region in the highly diverse env 
and IGH genes. TMIseq improves accuracy and increases read length to >800bp on 
the Illumina platform by using molecular identifiers and a custom Tn5 reaction to 
guide amplicon assembly. Previous methods were limited to shorter reads (~450bp) 
on the Illumina platform or lower accuracy with 454-pyrosequencing (Di Giallonardo 
et al., 2014; Li et al., 2014). The application of TMIseq to immunogenic regions of 
env controls for sampling error that could account for unusual sequence variants, such 
as the extra disulfide bonds described in Chapter 1 and Chapter 2. TMIseq can also be 
used to sequence the IGH VDJ region, including a portion of the C region for 
identification of antibody isotypes. Characterization of antibody repertoires in elite 
neutralizers and/or viral controllers could help elucidate the adaptive immune 
response that leads to the production of bNAbs or improved disease outcomes. Here, 
we present initial results demonstrating TMIseq can successfully be applied to the 
most variable region of env and used to explore antibody repertoires for different 
disease phenotypes. 
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Materials and methods 
Whole blood sample from one HIV-positive elite neutralizer (GSID001), one HIV-
positive non-elite neutralizer (GSID007), and two HIV-negative individuals (Control 
1 and Control 2) were processed by Ficoll gradient (GE Healthcare). Plasma and 
PBMCs were stored at -80°C. Proviral env V1 – V3 region was sequenced from 
GSID007 sample. All four samples were used for antibody repertoire sequencing. 
For proviral sequences, DNA was extracted from PBMCs with QIAamp DNA 
Mini Blood kit using standard QIAcube protocol (Qiagen) and gp160 was pre-
amplified in a 15-cycle PCR reaction with Phusion polymerase (Thermo Fisher 
Scientific). For IGH sequences, RNA was extracted from plasma with QIAamp Viral 
RNA Mini kit and reverse transcribed with SuperScript III (Thermo Fisher 
Scientific). In a 2-cycle PCR reaction, V1 – V3 region or IGH VDJ region was 
amplified with primers containing unique 16-base barcodes and partial Nextera 
sequences. 
PCR products >300bp were purified with Select-a-Size DNA Clean & 
Concentrator (Zymo Research). In a 30-cycle PCR reaction, PCR products were 
amplified with primers that completed the partial Nextera sequences. PCR products 
>300bp were purified with Select-a-Size DNA Clean & Concentrator (Zymo 
Research) and run on 1% agarose gel. 
Tn5 enzymes were loaded with either Nextera A adapters or Nextera B 
adapters. Separate transposase reactions randomly cleaved and tagged double-
stranded DNA with either Nextera A or B adapter overhangs (referred to as “A cut” 
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and “B cut”). Tagmentation products were PCR amplified using Nextera primers. 
Products were purified with DNA Clean & Concentrator (Zymo Research) and run on 
2% EX gel (Life Technologies). DNA ranging from 300bp – 900bp was extracted 
from the gel and purified using QIAquick Gel Extraction kit (Qiagen). Uncut DNA, 
Tn5 A cut, and Tn5 B cut libraries were pooled and sequenced according to standard 
Illumina protocols on an Illumina MiSeq. 
 
Results and discussion 
Proviral TMIseq of gp120 V1 – V3 regions 
Targeted amplicon sequencing can detect the frequency of unusual variants and 
provide information on the evolution of immunologically significant regions, such as 
the V1 – V3 region.  However, high-throughput sequencing introduces PCR errors 
and requires assembly, which are challenging problems to overcome in the highly 
diverse HIV population. Here, we applied TMIseq to improve accuracy over an 
~800bp region. To correct for PCR errors, we attached molecular barcodes (16 
random nucleotides) prior to amplification with out-nested primers (Bhiman et al., 
2015; Cole et al., 2016; Jabara et al., 2011). Unique barcodes attached to each end of 
the DNA template allowed us to correct for recombination, allelic skewing, and 
sequencing errors. Molecular barcodes were also used to assemble Illumina reads 
with a modified version of the protocol described in Cole et al, 2016. While 454 
pyrosequencing reads are long enough to cover the V1 – V3 region without assembly, 
454 pyrosequencing has lower yields, is less sensitive and has a higher false positive 
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rate than Illumina sequencing (Di Giallonardo et al., 2014; Li et al., 2014). To use the 
Illumina platform, we designed three separate library preps. The first library prep 
followed the standard Illumina protocol after adding the molecular barcodes (Figure 
3.1). This yielded high coverage at the ends (but insufficient coverage in the middle) 
and allowed us to match the 5’ and 3’ barcodes that came from each template. The 
other 2 library preps used custom transposase reactions to manipulate Illumina’s 
tagmentation step. Transposase reactions randomly cleaved and tagged double-
stranded DNA with either Illumina Nextera A or Illumina Nextera B adapters, 
resulting in varying lengths of DNA that ensured high coverage over the entire V1 – 
V3 region (Figure 3.2). Uncut DNA, DNA cut and tagged with Nextera A adapters, 
and DNA cut and tagged with Nextera B adapters were pooled and sequenced 
according to standard Illumina protocols on an Illumina MiSeq (Figure 3.3). The 
reads were assembled with custom scripts using the molecular barcodes with high 
coverage throughout the V1 – V3 region (Figure 3.3 and Figure 3.4). 
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Fig 3.1. Amplification of gp120 V1-V3 region for TMIseq. 
DNA was extracted from sample GSID007. V1 – V3 region was PCR amplified with 
unique molecular identifiers, purified, and run on 2% EX gel (Life Technologies). 
 
 
Fig 3.2. Transposase digest of gp120 V1 – V3 region library for TMIseq. 
Tn5 enzymes randomly cleave GSID007 V1 – V3 amplicons. Tagmentation products 
of different sizes were amplified, purified, and run on 2% EX gel (Life 
Technologies). 
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 (A)      (B) 
 
Fig 3.3. Read coverage of gp120 V1 – V3 region. 
Histograms of (A) trimmed raw read coverage and (B) unique identifier (UID) 
coverage mapped to HXB2 reference. 
 
 
 
 
Fig 3.4. Proviral V1 – V3 region TMIseq results. 
Proof of concept study yielded proviral consensus sequence for patient GSID007. V1 
– V3 sequences from plasma (Monog) and proviral (Illum) are shown. 
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Antibody repertoires from an elite neutralizer and HIV-positive individual that 
did not produce bNAbs  
A proof of concept study was conducted on an elite neutralizer and non-elite 
neutralizing normal progressor. Both HIV-positive individuals had a high proportion 
of IgG antibodies compared to controls (Fig 3.5) with significant somatic 
hypermutation (Fig 3.6), an expected result in response to HIV infection. 
Interestingly, the non-elite neutralizing individual showed highly mutated IgD 
antibodies (Fig 3.6). Longer CDRH3s were found in both HIV-positive subjects 
compared to controls (Fig 3.7). Further investigation is needed to characterize the 
antibody repertoires by disease phenotype, which may elucidate features that led to 
neutralization breadth. Current immunization strategies involve a series of 
vaccinations, where some mimic the evolution of the virus in attempt to shape 
antibody maturation (Liao et al., 2013). Characterization of antibody repertoires from 
different disease phenotypes may help resolve whether sustained selection pressure is 
necessary for the development of broadly neutralizing antibodies. 
  
 114 
Fig 3.5. Proportion of antibody isotypes in the antibody repertoires of an HIV-
positive elite neutralizer and a non-elite neutralizer. 
 
Fig 3.6. Somatic hypermutation in the antibody repertoires of an HIV-positive 
elite neutralizer and a non-elite neutralizer. 
 
Fig 3.7. CDRH3 lengths in the antibody repertoires of an HIV-positive elite 
neutralizer and a non-elite neutralizer. 
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Conclusion 
A primary focus of HIV vaccine research is to engineer immunogenic Env proteins. 
However, properly folded and glycosylated Env trimers have so far failed to elicit 
bNAbs. Envs are inherently poor immunogens and new strategies are needed in order 
to elicit an effective immune response. Here, we use Envs isolated from individuals 
with the elite neutralizer/controller phenotype and found unusual, potentially 
immunogenic structural features that may have contributed to the production of 
bNAbs and viral control. 
We identified individuals with the rarely reported elite neutralizer/controller 
phenotype from the SCOPE and WIHS longitudinal studies. In the WIHS cohort, we 
demonstrated that elite controllers as a group had lower neutralization breadth and 
potency compared to viremic controllers and normal progressors. The low level of 
viremia in elite controllers is less likely to provide sufficient antigenic stimulation to 
produce bNAbs but there was not a linear relationship between neutralization breadth 
and viral load. While elite controllers are less likely to produce bNAbs, we identified 
an elite controller with broadly neutralizing activity from the SCOPE cohort, one of 
the few individuals that have been reported with this phenotype. 
From the 78 individuals screened, two controllers with broadly neutralizing 
activity, EN3 and EN6, were selected for in depth analysis in an effort to identify 
Envs that may recapitulate their immune response. We studied viral controllers in part 
because they may have restricted evolution (Bailey et al., 2006; Bello et al., 2007, 
2004; Casado et al., 2010; Lassen et al., 2009; Roy et al., 2017; Sandonís et al., 2009; 
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Scutari et al., 2018; Smith et al., 2013; Wang et al., 2003) and, therefore, 
contemporaneous Envs may be more closely related to ancestral variants that elicited 
the production of bNAbs. We found low genetic diversity in both EN3 and EN6 Env 
populations (99.1% and 99.6% pairwise identity, respectively), however, longitudinal 
studies and high-throughput sequencing (e.g., TMIseq) are needed to determine if 
evolution was in fact limited. We also reasoned that viral controllers may have 
features that enhance immunogenicity, such as those that contribute to improved 
antigen presentation. Both EN3 and EN6 had Envs with highly unusual features in 
immunodominant regions. 
EN3 and EN6 had proviral Envs with elongated V1 regions containing two 
non-conserved cysteines, a feature found in only 5.5% of clade B viruses (van den 
Kerkhof et al., 2016). Mutagenesis experiments in EN3 demonstrated that mutations 
are necessary to accommodate the cysteine in order to preserve infectivity, suggesting 
a functional role. It appears the additional cysteines may arise from a duplication 
event and provide viral escape from V3-targeting antibodies but further investigation 
is needed. During these studies, we discovered the K170E polymorphism was a mode 
of escape from V2-glycan targeting bN-mAbs, PG9 and PG16. 
Envs isolated from EN6 plasma had a 35% reduction in potential N-linked 
glycosylation sites. The absence of glycans has been associated with the T/F 
phenotype, bNAb-inducing Envs, and increased immunogenicity (Chohan et al., 
2005; Dacheux et al., 2004; Derdeyn et al., 2004; Wu et al., 2006; Zhou et al., 2017). 
These previous findings have led to substantial effort in engineering Envs with fewer 
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glycans, which have improved neutralization response in rabbits and macaques (Koch 
et al., 2003; Li et al., 2008; Liang et al., 2016). Here, we identified a native, 
minimally glycosylated Env that elicited an improved cross-clade neutralization 
response in rabbits when compared to EN3 Env and reference Env, MN. 
Future research can build on this work by using the minimally glycosylated 
EN6 Env in alternate modes of immunization, including trimeric gp140s (Dey et al., 
2018; Sanders et al., 2013; Sliepen et al., 2019) in sequential immunization regimens 
(Dubrovskaya et al., 2019; Jardine et al., 2013; Steichen et al., 2016), and vector 
prime with rgp120 boosts (Barouch and Picker, 2014; Stephenson et al., 2016). The 
early results described in these studies provide evidence that elite 
neutralizer/controllers have unusual structural features that may have enhanced their 
immune response. Furthermore, this work demonstrated that individuals with the elite 
neutralizer/controller phenotype are a promising new source of HIV vaccine 
immunogens. 
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